Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
  • G01N33/56966—Animal cells
  • G01N33/56972—White blood cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2800/00—Detection or diagnosis of diseases
  • G01N2800/28—Neurological disorders
  • G01N2800/2814—Dementia; Cognitive disorders
  • G01N2800/2821—Alzheimer
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2800/00—Detection or diagnosis of diseases
  • G01N2800/28—Neurological disorders
  • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2800/00—Detection or diagnosis of diseases
  • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

• Parkinson's disease affects more than half a million Americans each year. Parkinson's disease is characterized by slowness of movement (bradykinesia), tremor at rest, rigidity of the extremities and neck, stooped posture, minimal facial expressions, problems swallowing (dysphagia), and a paucity of associated movements (e.g., arm swinging). Some patients also experience dementia associated with such abnormalities of motor function. Parkinson's disease is age-dependant and usually has a gradual onset between the ages of 50 and 70, progressing slowly until death 10 to 20 years later.
• Alzheimer's disease is another common neurodegenerative disease. Progression of Alzheimer's disease is associated with gradual changes of consciousness, loss of memory, perception, and orientation as well as loss of personality and intellect. The prevalence of Alzheimer's disease increases dramatically with age. 5. Accurate and easy diagnosis of neurodegenerative diseases prior to autopsy is challenging. Also, the etiology of many neurodegenerative diseases, such as Parkinson's and Alzheimer's disease, is not fully understood. Further, the symptoms associated with one neurodegenerative disease are oftentimes similar to the symptoms of other neurodegenerative diseases, especially at the early stages of disease. Such difficulties can cause confusion and complications with diagnosing and treating patients with such neurodegenerative diseases.
• the changes that take place in the neural fibers of the Alzheimer's patient are typically positively diagnosed upon histological analysis of the morphological changes that take place in the neurons. It has been shown that gene expression in an Alzheimer's brain changes and that ⁇ flj ⁇ s ⁇ biEibli%i5ssi ⁇ n!ba!HiOi ⁇ !sed to identify the onset and progression of an Alzheimer's patient. However, this type of analysis requires obtaining a brain sample from the patient, and is therefore, most useful in a post mortem setting.
• compositions and methods for differentiating, diagnosing, and monitoring neurodegenerative diseases are needed in the art.
• methods and compositions for the diagnosis of neurodegenerative diseases such as Parkinson's and Alzheimer's that involve sampling of the peripheral blood of the patient, rather than sampling neural tissue.
• the disclosed subject matter in one aspect, relates to compounds and compositions and methods for preparing and using such compounds and compositions.
• the disclosed subject matter relates to methods for the diagnosis and prognosis of a neurodegenerative disease (e.g., Parkinson's and Alzheimer's) in a particular subject.
• the disclosed subject matter relates to methods of screening for a therapeutic agent for the treatment of a neurodegenerative disease.
• the disclosed subject matter relates to methods of monitoring a response to a neurodegenerative disease treatment in a subject, methods of identifying a risk for a neurodegenerative disease in a test subject, and methods of differentially diagnosing a neurodegenerative disease in a test subject.
• diagnostic assays for a neurodegenerative disease and chips, beads, and arrays that can be used in the methods disclosed herein, hi many examples, the compositions and methods disclosed herein involve the use of blood from a subject and the analysis of gene expression within the blood cells.
• FIGURES V. BRIEF DESCRIPTION OF THE FIGURES figures, which are incorporated in and constitute a part of this specification, illustrate several embodiments and together with the description illustrate the disclosed compositions and methods.
• Figure IA is a plot of canonical variables 1 and 2 for the first study.
• Canonical variables for this plot, and for Figures IB and 1C, were derived from data for the cell cycle related messages: cyclin Dl, cyclin B, cyclin Gl, weel, hTR2, CDC25b, GSK3 beta, and protein kinase C alpha.
• WaId- Wolfowitz runs test p ⁇ 0.05 for difference between Alzheimer's disease ("AD") and control cases ("Con”). The cases included are shown in Table 1.
• Figure IB is a plot of canonical variables 1 and 2 for the second study. Canonical variables for this plot were derived from data for the same cell cycle related messages as in Figure IA. WaId- Wolfowitz runs test p ⁇ 0.05 for difference between AD and control cases. The cases included are shown in Table 2.
• Figure 1C is a plot of canonical variables 1 and 2 for the third study.
• Canonical variables for this plot were derived from data for the same cell cycle related messages as in Figure IA. WaId- Wolfowitz runs test p ⁇ 0.05 for difference between AD and control cases. The cases included are shown in Table 3.
• Figure 2 A is a plot of canonical variables 1 and 2 for the first study.
• Canonical variables for this plot were derived from data for the inflammatory related messages: C5, Cl inhibitor, C5a, complement C3, cyclooxygenase 1, IL17, IL8, LIF, TNF alpha, and ILlOr.
• WaId- Wolfowitz runs test p ⁇ 0.05 for difference between AD and control cases. The cases included were the same as for Figure IA.
• variables 1 and 2 for the second study Canonical variables for this plot were derived from data for the same inflammatory related messages as in Figure 2A.
• WaId- Wolfowitz runs test p ⁇ 0.05 for difference between AD and control cases.
• the cases included were the same as for Figure IB. 15.
• Figure 2C is a plot of canonical variables 1 and 2 for the third study.
• Canonical variables for this plot were derived from data for the same inflammatory related messages as in Figure 2A. WaId- Wolfowitz runs test p ⁇ 0.05 for difference between AD and control cases. The AD and control cases included were the same as for Figure 1C. Two Parkinson's disease (“PD") cases were added here. 16.
• Figure 3 is a group of plots of the first canonical variable for the initial set of 8 AD and 7 control subjects (see Table 1).
• the transcripts related to cell cycle in the multivariate analysis were: cyclin Dl, cyclin B, cyclin Gl, weel, hTR2, CDC25b, GSK3 beta, and protein kinase C alpha.
• the transcripts related to inflammatory systems in the multivariate analysis were: C5, Cl inhibitor, IL-17r, IL-8, LIF, TNF-alpha, and IL-IOr.
• the transcripts related to cell stress in the multivariate analysis were: Alpha-1 antichymotrypsin, HSP 27, HSP 90, crystalline, GAPDH, ferritin H, ferritin L, cox 1, cox 2, and transferrin, hi all three plots WaId- Wolfowitz runs test p ⁇ 0.05 for difference between early AD and control cases.
• Figure 4 is a group of plots of the first canonical variable for the second set of subjects (8 AD and 8 controls; see Table 2). The transcripts are the same as in Figure 3. In all three plots WaId- Wolfowitz runs test p ⁇ 0.05 for difference between early AD and control cases.
• Figure 5 is a group of plots of the first canonical variable for the third set of subjects (5 AD, 5 controls, and 2 PD). The transcripts are the same as in Figure 3. In all three plots WaId- Wolfowitz runs test p ⁇ 0.05 for difference between early AD and control cases.
• Figure 6 is a silver stained 2D electrophoresis gel. Difference Image of 2 independent human white blood cell samples showing spots present only in one sample but not the other.
• Figure 7 is a MALDI-TOF mass analysis of isolated differentially expressed protein.
• FIG. 8 is a series of graphs showing differential expression of peripheral leukocyte protein spots from the full cohort of control ("CTL") and Parkinson's disease subjects.
• CTL control
• PD PD
• Figures 1OA, 1OB, 1OC, and 1OD are four scanned images of two-dimensional (2D) protein gels that have been silver-stained and dried.
• Figure 1OA is an image showing the levels of proteins expressed in leukocytes obtained from an Alzheimer's patient prior to treatment with valproate (VPA).
• Figure 1OB is an image showing proteins expressed in leukocytes from the same patient four weeks after initiating VPA treatment.
• Figures 1OC and 1OD are enlarged versions of the images of Figures 1OA and 1OB, respectively, after the images were processed using protein spot-detection software. Spots labeled #278 in Figures 1OC and 1OD are the spots of a differentially expressed protein before VPA treatment and after VPA treatment.
• Figure 11 is a chart listing examples of biomarkers identified using the methods disclosed herein.
• Figure 12 is a set of four histograms quantifying the effects of the indicated VPA concentrations on expression of four candidate biomarkers in cultured leukocytes. Three of the four proteins identified as biomarkers in VPA-treated patients also demonstrated changes in expression in response to treatments with increasing doses of VPA.
• Ranges can be expressed herein as from “about” one particular value, and/or to "about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about,” it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10" is also disclosed.
• Probes are molecules capable of interacting with a target nucleic acid, typically in a sequence specific manner, for example through hybridization. The hybridization of nucleic acids is well understood in the art and discussed herein. Typically a probe can be made from any combination of nucleotides or nucleotide derivatives or analogs available in the art.
• Primers are a subset of probes which are capable of supporting some type of enzymatic manipulation and which can hybridize with a target nucleic acid such that the enzymatic manipulation can occur.
• a primer can be made from any combination of nucleotides or nucleotide derivatives or analogs available in the art which do not interfere with the enzymatic manipulation.
• USOEteftSIiSM ⁇ bs “elevates,” or “raises” refer to levels above control or reference levels. The terms can also include the appearance or occurrence of an event (e.g., a level above a control or reference level that is zero).
• the terms “decreases,” “reduces,” or “lowers” refer to levels below control or reference levels. These terms can also include the absence or ablation of an event (e.g., a level of zero when a control or reference level is not zero).
• subject and patient are used interchangeably and mean an individual.
• subject or patient can include domesticated animals (e.g., cats, dogs, etc.), livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), laboratory animals (e.g., mouse, rabbit, rat, guinea pig, etc.), and birds.
• subject or patient can also include a mammal, such as a primate.
• a "subject” or “patient” can be a human.
• sample refers to any biological material obtained from a subject or patient.
• a sample can comprise blood, cerebrospinal fluid ("CSF"), or urine.
• CSF cerebrospinal fluid
• a sample can comprise whole blood, plasma, leukocytes enriched from blood samples, and cultured cells (e.g., leukocytes from a subject).
• a sample can also include a biopsy or tissue sample including neural tissue.
• a sample can comprise whole cells and/or a lysate of the cells. Examples of cells include, but are not limited to, leukocytes such as neutrophils, monocytes, basophils, lymphocytes, eosinophils, or any combination thereof.
• a sample can comprise a leukocyte or substantially pure population of leukocytes or a lysate thereof.
• the term "substantially pure" with respect to a population of leukocytes or lysates thereof is intended to refer to a sample that contains less than about 1%, less than about 5%, less than about 7%, less than about 10%, less than about 12%, less than about 15%, less than about 20%, less than about 25%, or less than about 30% of cells other than leukocytes, based on the total number of cells in the sample.
• a sample can comprise lymphocytes, a substantially pure population of lymphocytes, or a lysate of a substantially pure population of lymphocytes.
• the leukocytes can be enriched for a selected type.
• the leukocyte population can be enriched for lymphocytes and used in the methods described herein. Enrichment can be accomplished using cell sorting techniques like FACS. 37.
• neurodegenerative disease is meant any disease characterized by the dysfunction and/or death of neurons leading to a loss of neurologic function in the brain, spinal cord, central nervous system, and/or peripheral nervous system. Neurodegenerative diseases can be chronic or acute.
• neurodegenerative diseases include, but are not limited to, Parkinson's Q ⁇ essyffio ⁇ dterrtpiofi ⁇ libSeitias, firontotemporal dementia and Parkinsonism, Alzheimer's disease, Mild Cognitive Impairment, Diffuse Lewy body disease, Dementia with Lewy bodies type, demyelinating diseases such as multiple sclerosis and acute transverse myelitis, amyotrophic lateral sclerosis, Huntington's disease, Creutzfeldt- Jakob disease, AIDs dementia complex, extrapyramidal and cerebellar disorders such as lesions of the corticospinal system, disorders of the basal ganglia, corticobasal ganglionic degeneration, peripheral neuropathy (secondary to diabetes or chemotherapy treatment), progressive supranuclear Palsy, structural lesions of the cerebellum, spinocerebellar degenerations, such as spinal ataxia, Friedreich's ataxia, cerebellar cortical degenerations, multiple
• Some examples of acute neurodegenerative disease are stroke, ischemia, and multiple infarct dementia. Sudden loss of neurons may also characterize the brains of patients with epilepsy and those that suffer hypoglycemic insults and traumatic injury of the brain, peripheral nerves, or spinal cord.
• biomarkers including methods for identifying and using biomarkers.
• the disclosed biomarkers can be used in (i) methods of diagnosing neurodegenerative diseases (e.g., Parkinson's disease and Alzheimer' disease), (ii) methods of tracking the progression of a neurodegenerative disease, (iii) methods of monitoring the response of a subject to a treatment for a neurodegenerative disease, (iv) methods of !4dinri ⁇ il ' Mitf6i"JiMidlgenerative disease, (v) methods of distinguishing one neurodegenerative disease from another, and several other methods, as are disclosed herein.
• neurodegenerative diseases e.g., Parkinson's disease and Alzheimer' disease
• methods of tracking the progression of a neurodegenerative disease e.g., Alzheimer' disease
• methods of monitoring the response of a subject to a treatment for a neurodegenerative disease e.g., a treatment for a neurodegenerative disease
• iv methods of !4dinri ⁇ il ' Mitf6i"J
• biomarker is meant any assayable characteristic or composition that can be used to identify a condition (e.g., a neurodegenerative disease or lack thereof) or the status of a condition in a subject or sample.
• a biomarker can, in some examples disclosed herein, be a gene whose expression characteristics can be used to identify a condition or status of a condition in a subject or sample.
• a biomarker can be a gene product.
• gene product is meant a transcript, nucleic acid, or protein.
• a biomarker can be a gene product whose presence or absence in a subject is characteristic of a subject having or not having a particular neurodegenerative disease, having a particular risk for developing a neurodegenerative disease, or being at a particular stage of disease.
• a biomarker can be a gene product whose increase or decrease indicates a particular neurodegenerative disease, a particular risk for developing a neurodegenerative disease, or a particular stage of disease.
• a biomarker can be a group of various gene products, the presence or absence of which is indicative of a subject having or not having a particular neurodegenerative disease, having a particular risk for developing a neurodegenerative disease, or being at a particular stage of disease.
• a biomarker can be a group of gene products whose pattern of increasing and decreasing expression characterizes a particular neurodegenerative disease or lack thereof. Still further, a biomarker can be a gene product or group of gene products whose pattern of expression is characteristic of the presence or absence of a neurodegenerative disease, or a particular prognosis or outcome of a disease. As used herein, a biomarker can be a surrogate for other clinical tests. Biomarkers identified herein can be measured to determine levels, expression, activity, or to detect variants. As used throughout when detecting levels of expression or activity are discussed, it is understood that this could reflect variants of a given biomarker. Variants include amino acid or nucleic acid variants or post translationally modified variants.
• nucleic acid e.g., transcript
• protein is also disclosed, unless explicitly stated to the contrary or as would be understood by one of ordinary skill in the art based on the context.
• nucleic acid e.g., transcript
• protein is also disclosed.
• proteins, nucleic acids, and transcripts Ii ⁇ li#i,4 ' ⁇ ifliil i iik ⁇ ; fy"lnd collectively, unless explicitly stated to the contrary or as would be understood by one of ordinary skill in the art based on the context.
• a biomarker can be a particular gene product, or a particular level or amount of a gene product
• a biomarker can also be a particular variable (e.g., a first and/or second canonical variable) obtained when the levels or amounts of such gene products are analyzed in a multivariant canonical analysis.
• biomarkers for a neurodegenerative disease such as Alzheimer's or Parkinson's are used to diagnose the disease in subjects.
• profiles of message expression by single neurons or homogenates from postmortem human brain can be used to distinguish neurodegenerative diseases from control samples (see e.g.,
• Alzheimer's Disease Center as having probable AD and from an age and sex matched control sample.
• Messenger RNA was extracted from leukocytes and amplified. The expression level of selected messages was then quantified using low density arrays. Multivariate canonical analyses differentiated Alzheimer's and control leukocytes. The message species studied also differentiated two Parkinson's disease cases from AD and control samples. These results illustrate the additional accuracy that may be derived by a biomarker that makes use of multiple variables. Of the classes of mRNA species examined, those that best distinguished AD from control leukocytes were those involved in the cell cycle and in inflammatory processes. That members of these same classes also distinguish AD from control brains is consistent with understanding selected phenomena of the brain in Alzheimer' s disease without actually invading the brain.
• a similar example was performed with patients diagnosed with Parkinson's disease, as is disclosed herein. Specifically, fresh whole blood was drawn from a patient population that II agi ⁇ i&lllii : lontrol patients. Leukocyte protein concentrations were determined and protein spots that differed in intensity between PD and control patients were identified using Progenesis Discovery software (Nonlinear USA, Inc.; Durham, NC). Difference measurements were subjected to statistical testing. Protein spots were identified as either increasing or decreasing in Parkinson's disease compared with control. Differentially expressed spots were isolated and identified. The results show that protein analysis from peripheral blood can be used to diagnose neurodegenerative diseases such as PD.
• compositions and methods disclosed herein are based on the identification that the expression of certain genes in samples (e.g., blood) from a subject with a neurodegenerative disease is altered.
• the disclosed methods typically involve comparing the expression of certain genes and sets of genes in the blood of a subject to the expression of the same gene or sets of genes in a control sample.
• the control sample can be a non- neurodegenerative diseased subject concurrently run, or it can be a standard created by assaying one or more non-neurodegenerative diseased subjects and collecting the expression data.
• the control sample thus, can be a standard, which is created and used continuously.
• a standard could be created by the expression profiles of non-AD or non-PD cases disclosed herein.
• the standard could include, for example, the average level of expression of a gene or particular set of genes in non-neurodegenerative diseased subject or any other control group.
• a neurodegenerative disease e.g., Parkinson's or Alzheimer's disease
• the disclosed methods can comprise assessing a level of expression or activity of one or more selected biomarkers (e.g., gene products) in a sample, for example a sample comprising leukocytes or a lysate thereof, from the subject to be diagnosed and comparing the level of expression or activity of the selected biomarker(s) to a reference standard that indicates the level of expression or activity of the selected biomarker(s) in one or more control subjects, m these methods, a difference or similarity between the level of expression or activity of the selected biomarker(s) and the reference standard can indicate that the subject has or does not have a particular neurodegenerative disease, depending on the particular reference standard.
• biomarkers e.g., gene products
• the subject can be as described herein, for example, any individual, such as a human.
• the subject is to be diagnosed for a particular neurodegenerative disease.
• the subject to be diagnosed can have symptoms of a particular neurodegenerative disease or the subject can be asymptomatic or preclinical for a particular neurodegenerative disease (e.g., Parkinson's or Alzheimer's disease).
• the control subject can be a subject with a particular neurodegenerative disease (e.g., Parkinson's or Alzheimer's disease), at a particular stage of a disease, with a particular risk of developing a disease, or without a particular neurodegenerative disease.
• a particular neurodegenerative disease e.g., Parkinson's or Alzheimer's disease
• the subject to be diagnosed and a control subject can be age-matched and/or sex matched.
• a control subject i.e., reference standard
• a difference or similarity in the level of the biomarker(s) expression or activity can be determined by any quantitative or qualitative comparative analysis between the levels of one or more selected biomarker(s) in the sample and in the reference standard. For example, when the control subject has a particular neurodegenerative disease, then when using the disclosed methods, a similarity between the level of the biomarker(s) in the subject and the control subject can indicate that the subject to be diagnosed also has the particular neurodegenerative disease. In another example, when the control subject has a particular neurodegenerative disease, then when using the disclosed methods, a difference between the level of the biomarker(s) in the subject and the control subject can indicate that the subject to be diagnosed does not have the particular neurodegenerative disease.
• a difference between the level of the biomarker(s) in the subject and the control subject can indicate that the subject to be diagnosed has the particular neurodegenerative disease.
• a similarity between the level of the biomarker(s) in the subject and the control subject can indicate that the subject to , be diagnosed does not have the particular neurodegenerative disease.
• a selected gene product was identified as a biomarker by detecting an increase in expression or activity of the gene product in subjects diagnosed with a neurodegenerative disease, for example, Parkinson's or Alzheimer's disease, then an increase in standard) of the biomarker in a sample from a subject can indicate that the subject has the neurodegenerative disease.
• an increase in standard of the biomarker in a sample from a subject can indicate that the subject has the neurodegenerative disease.
• a decrease in expression or activity of the gene products in subjects diagnosed with the neurodegenerative disease then a decrease (relative to the reference standard) in expression of the protein(s) in a sample from a subject can indicate that the subject has the neurodegenerative disease.
• biomarkers can be use in the disclosed methods.
• one or more biomarkers can increase and other biomarkers can decrease relative to the reference standard and can thus indicate the presence or absence of a neurodegenerative disease.
• the methods disclosed herein typically involve collecting a sample from a subject.
• the sample can be of the peripheral blood of a subject, though the uses of other samples are contemplated.
• a blood sample can be collected in any way that allows for isolation of cells and, subsequently, gene products from these cells.
• the blood can be collected and via syringe, and then stored at 4°C.
• Blood samples can be collected in evacuated tubes containing, but not limited to, heparin, EDTA or ADC (yellow tube) or any other anticoagulant.
• Another way to collect and store blood can be achieved through the use of PAXgeneTM Blood RNA tubes, which allows the stabilization and the storage of whole blood for up to 5 days at room temperature.
• the pellet can be re- suspended by vortexing at 4°C in 200 ⁇ L buffer (20 niM Tris, pH 7.5, 0.5% Nonidet, 1 mM EDTA, 1 mM PMSF, 0.1 M NaCl, IX Sigma Protease Inhibitor, and IX Sigma Phosphatase Inhibitors 1 and 2).
• the suspension can be kept on ice for 20 minutes with intermittent vortexing. After spinning at 15,000 x g for 5 minutes at 4°C, aliquots of supernatant can be stored at minus 70°C.
• the collection of other types of samples e.g., urine, CSF, tissue, etc., can be performed by methods known in the art.
• the various cells contained within the sample can be separated.
• the expression pattern of a gene or set of genes is assayed within a leukocyte population contained within the sample.
• Various cells can be isolated in any way, as long as the cells are ultimately preserved such that gene products can be collected from them. For example, one way of isolating leukocytes is lysing the erythrocytes .
• the assay can be applied to subtypes of leukocytes, such as lymphocytes and their subclasses, monocytes, and other types of blood cells.
• non-blood cells can be assayed, such as those from skin, cheek scrapings, muscle, olfactory epithelium, digestive system, urinary system, and reproductive system, for example.
• Lysing can occur in any way, including, for example, in RNAse free conditions through the use of ammonium chloride or using commercial reagents such as IMMUNOLYSETM and OPTILYSETM (Coulter International Corporation; Miami, FL).
• HISTOP AQUETM Sigma; Milwaukee, WI
• Another way to achieve this goal is allowing the anticoagulated blood to sediment for 1-2 hours at room temperature and collecting the leukocyte fraction.
• Another example of lysing includes centrifuging anticoagulated blood for about 5 minutes at 150-200 g; and then removing the buffy coat.
• the leukocytes can also be collected using, for example, leukocyte-specific markers for cell sorting.
• the general leukocyte population can be sorted into subtypes, for example, such as B cells, T cells, basophils, eosinophils, neutrophils, monophils, monocytes, and platelets, and subtypes of these general categories.
• Markers include, but are not limited to, MHC glycoproteins, integrins, homing receptors, Fc receptors for IgG, IgE, IgM, IgA, and IgD, complement receptors for lymphokines, interferons, colony stimulating factors, receptors for insulin, receptors for neurotransmitters, chemotactic receptors, membrane enzymes, and transport proteins. These can be sorted, for example, by antibodies that recognize the more than 170 CD antigens.
• Leukocyte nucleic acid can be also collected using 4M guanidinium isothiocyanate lysis and cesium chloride ultracentrifugation, for example, or using 4 M guanidine thiocyanate/ 25 mM sodium citrate/ 0.5% Sarkosyl / 0.1 M /3-mercaptoethanol to lyse the leukocytes and then adding 2M NaOAc prior to centrifugation steps and isopropanol precipitation.
• nucleic acids can be collected using hydroxy appetite or they can be collected using positively charge magnetic beads. Nucleic acids can also, for example, be precipitated. Total RNA can also be obtained using TRIZOLTM reagent (Gibco Life Technologies, Inc.; Rockville, MD), which is a mono- phasic solution of phenol and guanidine isothiocyanate. Any other reagent that maintains the ⁇ lke
• Leukocyte proteins and peptides can also be collected by lysing cells in "crack buffer” (50 mM Tris-HCl (pH 6.8), 100 mM DTT 5 100 ⁇ g/ml PMSF, 2% sodium dodecyl sulfate (SDS), 10% glycerol, 1 ⁇ g/ml each of pepstatin A, leupeptin, and aprotinin, and 1 M sodium orthovanadate), and sheared with a 22 gauge needle.
• the protein content of the samples can be estimated using the DC protein assay (BioRad). Protein (10-20 ⁇ g) can be resolved using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with 10% SDS.
• the total gene product (e.g., biomarker) will be first isolated or collected. This can be done using any means for collecting nucleic acids and/or proteins. Once the gene products are collected, they can be washed, and, for example, eluted, if they are to be attached to a type of affinity system, such as magnetic beads. The step of collecting gene products is typically done to acquire the rnRNA and/or proteins in the sample, and is not needed if direct collection of the gene product is used. The gene products can be prepared, however, in any way that allows for analysis of gene expression. c) Preparation of the RNA
• the disclosed methods involve some level of RNA preparation.
• the RNA preparation step is not required to be performed as part of a contiguous method, but in certain methods the RNA should be prepared such that it can be hybridized.
• the RNA can be used to produce cDNA, which can then be used, for example, as a template for a PCR reaction or directly analyzed through, for example, hybridization of a probe.
• RNA preparation step could be performed far removed from the actual amplification and quantitation steps (e.g., in another laboratory, or at a much earlier time), in many embodiments the RNA isolation and preparation, or amplification of cDNA etc., will occur in conjunction with the amplification and quantitation steps of the methods, such as PCR or hybridization; but this is not required.
• the method of RNA preparation can be any method of RNA preparation that produces enzymatically manipulatable mRNA or analyzable RNA.
• the RNA can be isolated by using the guanidinium isothiocyanate-ultracentrifugation method, the guanidinium and phenol-chloroform method, the lithium chloride-SDS-urea method or poly A+ / mRNA from tissue lysates using oligo(dT) cellulose method. It is important when isolating the RNA that enough RNA is isolated. Furthermore, typically the quantity of RNA obtained can be determined.
• the number of cycles of PCR that are performed so as to continue to remain at about the doubling rate is related to the amount of total RNA that was used in the cDNA generation step.
• RNA can be isolated from any desired cell or cell type and from any organism, including mammals, such as mouse, rat, rabbit, dog, cat, monkey, and human, as well as other non-mammalian animals, such as fish or amphibians, as well as plants and even prokaryotes, such as bacteria. d) RNA expression analysis
• the expressed messenger RNA contained within these cells can be assayed. This can be done using any of a number of means, such as hybridization, Northern blot, RT-PCR, real-time RT-PCR, single channel quantitative multiplex RT-PCR, oligo- and/or cDNA arrays or any technology that can lead to nucleotide quantification.
• An example of such an approach can be derived from automated instruments based on the use of DNA-chip technologies, an example of which can be found at Integrated Nano-Technologies LLC, http://www.integratednano.com/.
• one way of assaying the total niRNA is to collect all of the nucleic acids contained within the cells, by for example, lysing the cells, and precipitating the nucleic acids.
• Messenger RNA can be collected in any way, such as using a polyT oligonucleotide, which will specifically hybridize with the polyA tail contained on messenger RNA transcripts. This method, however, relies on the presence of the 3'-polyA tail, but under certain conditions, this tail may be degraded.
• another way of directly analyzing all messenger RNA, including fragments can be to use message specific primers with reverse transcriptase to make cDNA.
• This cDNA can then be assayed directly or amplified and assayed by, for example, using quantitative PCR discussed herein. It is understood that the ultimate goal is the analysis of gene expression which can be accomplished in anyway which analyzes the expression of genes and compares their expression. It is understood that direct hybridization or other means of identification of mRNA is considered, as well as means where the mRNA is manipulated to form, for example, cDNA which is directly analyzed through, for example, hybridization or other identification, or which itself can be amplified producing, for example, a PCR product, which itself can be directly or otherwise identified or manipulated. As long as the end goal of identification of gene expression is realized it is contemplated herein.
• the analysis of the expression can be through, for example, hybridization of probes.
• probes for the specific genes to be analyzed can be contained on, for example, a chip, and the mRNA can be analyzed for binding to the chip. These chips are typically referred to as arrays, such as microarrays or macroarrays.
• An array is an orderly arrangement of samples, providing a medium for matching known and unknown DNA samples based on base-pairing rules. Typically the process of identifying the unknowns is automated.
• An array experiment can make use of common assay systems such as microplates or standard blotting membranes and can be created by hand or make use of robotics to deposit the sample.
• arrays are described as macroarrays or microarrays, the difference being the size of the sample spots.
• Macroarrays contain sample spot sizes of about 300 ⁇ m or larger and can be easily imaged by existing gel and blot scanners.
• the sample spot sizes in a microarray can be 300 ⁇ m or less, but typically less than 200 ⁇ m in diameter and these arrays usually contain thousands of spots.
• Microarrays typically require specialized robotics and/or imaging equipment that are generally constructed for each unique application of a microarray. Terminologies that have been used in the literature to describe this technology include, but are not limited to, biochip, DNA chip, DNA microarray, GENECHTPTM (Affymetrix's high density, oligonucleotide-based DNA array product (Affymetrix, Inc.; Santa Clara, CA)), and gene array.
• GENECHTPTM Affymetrix's high density, oligonucleotide-based DNA array product (Affymetrix, Inc.; Santa Clara, CA)
• DNA microarrays typically are fabricated by high-speed robotics, generally on glass or nylon substrates, for which probes with known identity are used to determine complementary binding, thus allowing massively parallel gene expression and gene discovery studies. An experiment with a single DNA chip can provide information on thousands of genes simultaneously. It is herein contemplated that the disclosed microarrays can be used for any purpose, including monitoring gene expression, disease diagnosis, gene discovery, drug discovery (pharmacogenomics), and toxicological research or toxicogenomics.
• Type II arrays there are two variants of the DNA microarray technology, in terms of the property of arrayed DNA sequence with known identity.
• the main difference between Type I and Type II arrays is that in a Type I array there is typically a single sequence or set of related sequences, such as a set of allelic sequences, and in Type II microarrays there are many different sequences attached to the surface.
• aprobe typically a cDNA (500 to about 5,000 bases long) that is immobilized to a solid surface such as glass using robot spotting and exposed to a set of targets either separately or in a mixture. This method is traditionally referred to as a DNA microarray.
• Type I microarrays localized multiple copies of one or more polynucleotide sequences, preferably copies of a single polynucleotide sequence are immobilized on a plurality of defined regions of the substrate's surface.
• a polynucleotide refers to a chain of nucleotides ranging typically from 5 to 10,000 nucleotides. These immobilized copies of a polynucleotide sequence are suitable for use as probes in hybridization experiments. The immobilized sequences are then probed with a number of different samples, typically at different regions of the chip, such that samples which contain nucleotides that hybridize to the immobilized sample can be identified.
• Typical dispensers include a micropipette delivering solution to the substrate with a robotic system to control the position of the micropipette with respect to the substrate.
• a microarray is formed by using ink-jet technology based on the piezoelectric effect, whereby a narrow tube containing a liquid of interest, such as oligonucleotide synthesis reagents, is encircled by an adapter.
• An electric charge sent across the adapter causes the adapter to expand at a different rate than the tube and forces a small drop of liquid onto a substrate (see Baldeschweiler, et al., PCT publication WO95/251116).
• Samples can be any sample containing polynucleotides (polynucleotide targets) of interest and obtained from any bodily fluid (blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations.
• DNA or RNA can be isolated from the sample according to any of a number of methods well known to those of skill in the art. For example, methods of purification of nucleic acids are described in Laboratory Techniques in Biochemistry and Molecular Biology: Hybridization with Nucleic Acid Probes. Part I. Theory and Nucleic Acid Preparation, P. Tijssen, ed. Elsevier (1993).
• total RNA is isolated using the TRIZOLTM total RNA isolation reagent (Gibco Life Technologies, Inc., Rockville, MD) and mRNA is isolated using oligo d(T) column chromatography or glass beads.
• TRIZOLTM total RNA isolation reagent Gibco Life Technologies, Inc., Rockville, MD
• mRNA is isolated using oligo d(T) column chromatography or glass beads.
• ⁇ -Afftef nybM ⁇ lzatidtf an® professing the hybridization signals obtained should reflect accurately the amounts of control target polynucleotide added to the sample.
• the plurality of defined regions on the substrate, immobilized polynulcoeotide, can be arranged in a variety of formats. For example, the regions may be arranged perpendicular or in parallel to the length of the casing.
• the targets do not have to be directly bound to the substrate, but rather can be bound to the substrate through a linker group.
• the linker groups may typically vary from about 6 to 50 atoms long. Suitable linker groups include ethylene glycol oligomers, diamines, diacids and the like. Reactive groups on the substrate surface react with one of the terminal portions of the linker to bind the linker to the substrate. The other terminal portion of the linker is then functionalized for binding the probes.
• Sample polynucleotides maybe labeled with one or more labeling moieties to allow for detection of hybridized probe/target polynucleotide complexes.
• the labeling moieties can include compositions that can be detected by spectroscopic, photochemical, biochemical, bioelectronic, immunochemical, electrical, optical or chemical means.
• the labeling moieties include radioisotopes such as 32 P, 33 P, or 35 S, chemiluminescent compounds, labeled binding proteins, heavy metal atoms, spectroscopic markers such as fluorescent markers and dyes, magnetic labels, linked enzymes, mass spectrometry tags, spin labels, electron transfer donors and acceptors, biotin, and the like.
• Labeling can be carried out during an amplification reaction, such as polymerase chain reaction and in vitro or in vivo transcription reactions. Alternatively, the labeling moiety can be incorporated after hybridization once a probe-target complex is formed.
• biotin is first incorporated during an amplification step as described above. After the hybridization reaction, unbound nucleic acids are rinsed away so that the only biotin remaining bound to the substrate is that attached to target polynucleotides that are hybridized to the polynucleotide probes. Then, an avidin-conjugated fluorophore, such as avidin- phycoerythrin, that binds with high affinity to biotin is added.
• an avidin-conjugated fluorophore such as avidin- phycoerythrin
• Hybridization causes a polynucleotide probe and a complementary target to form a stable duplex through base pairing.
• Hybridization methods are well known to those skilled in the art, and stringent conditions for hybridization can be defined by salt concentration, temperature, and other chemicals and conditions as discussed herein. Varying additional parameters, such as hybridization time, the concentration of detergent (sodium dodecyl sulfate, SDS) or solvent (formamide), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art.
• the polynucleotide probes are labeled with a fluorescent label and measurement of levels and patterns of complex formation is accomplished by fluorescence microscopy, such as confocal fluorescence microscopy.
• fluorescence microscopy such as confocal fluorescence microscopy.
• An argon ion laser excites the fluorescent label, emissions are directed to a photomultiplier, and the amount of emitted light detected and quantitated.
• the detected signal should be proportional to the amount of probe/target polynucleotide complex at each position of the microarray.
• the fluorescence microscope can be associated with a computer-driven scanner device to generate a quantitative two-dimensional image of hybridization intensities. The scanned image is examined to determine the abundance/expression level of each hybridized target polynucleotide. 75.
• polynucleotide targets from two or more different biological samples are labeled with two or more different fluorescent labels with different emission wavelengths. Fluorescent signals are detected separately with different photomultipliers set to detect specific wavelengths. The relative abundances/expression levels of the target polynucleotides in two or more samples are obtained.
• microarray fluorescence intensities can be normalized to take into account variations in hybridization intensities when more than one microarray is used under similar test conditions, hi one example, individual polynucleotide probe/target complex hybridization intensities are normalized using the intensities derived from internal normalization controls contained on each microarray.
• Type II microarrays comprise an array of oligonucleotides (e.g., from about 20 to about 80-mer oligos) or peptide nucleic acid (PNA) probes that is synthesized either in situ (on- chip) or by conventional synthesis followed by on-chip immobilization. The array is exposed to labeled sample DNA, hybridized, and the identity/abundance of complementary sequences is determined.
• This method "historically" called DNA chips, was developed at Affymetrix, Inc., (Santa Clara, CA), which sells its photolithographically fabricated products under the GENECHIP trademark.
• Type II arrays for gene expression is simple: labeled cDNA or cRNA targets derived from the mRNA of an experimental sample are hybridized to nucleic acid probes attached to the solid support. By monitoring the amount of lafl ⁇ lsl ⁇ eytfei ⁇ Wit ⁇ eafcffDNA location, it is possible to infer the abundance of each mRNA species represented.
• hybridization has been used for decades to detect and quantify nucleic acids, the combination of the miniaturization of the technology and the large and growing amounts of sequence information, have enormously expanded the scale at which gene expression can be studied.
• Microarray manufacturing can begin with a 5-inch square quartz wafer. Initially the quartz is washed to ensure uniform hydroxylation across its surface. Because quartz is naturally hydroxylated, it provides an excellent substrate for the attachment of chemicals, such as linker molecules, that are later used to position the probes on the arrays. 79. The wafer is placed in a bath of silane, which reacts with the hydroxyl groups of the quartz, and forms a matrix of covalently linked molecules. The distance between these silane molecules determines the probes' packing density, allowing arrays to hold over 500,000 probe locations, or features, within a mere 1.28 square centimeters. Each of these features harbors millions of identical DNA molecules. The silane film provides a uniform hydroxyl density to initiate probe assembly. Linker molecules, attached to the silane matrix, provide a surface that may be spatially activated by light.
• Probe synthesis occurs in parallel, resulting in the addition of an A, C, T, or G nucleotide to multiple growing chains simultaneously.
• photolithographic masks carrying 18 to 20 square ⁇ m windows that correspond to the dimensions of individual features, are placed over the coated wafer. The windows are distributed over the mask based on the desired sequence of each probe.
• ultraviolet light is shone over the mask in the first step of synthesis, the exposed linkers become deprotected and are available for nucleotide coupling.
• a solution containing a single type of deoxynucleotide with a removable protection group is flushed over the wafer's surface.
• the nucleotide attaches to the activated linkers, initiating the synthesis process.
• oligonucleotide can be occupied by 1 of 4 nucleotides, resulting in an apparent need for 25 x 4, or 100, different masks per wafer, the synthesis process can be designed to significantly reduce this requirement.
• Algorithms that help minimize mask usage calculate how to best coordinate probe growth by adjusting synthesis rates of individual probes and identifying situations when the same mask can be used multiple times.
• probes are selected from regions shared by multiple splice or polyadenylation variants. In other cases, unique probes that distinguish between variants are favored. Inter-probe distance is also factored into the selection process.
• a different set of strategies is used to select probes for genotyping arrays that rely on multiple probes to interrogate individual nucleotides in a sequence.
• the identity of a target base can be deduced using four identical probes that vary only in the target position, each containing one of the four possible bases.
• probe arrays with many probes can be created to provide redundant information, resulting in unequivocal genotyping.
• generic probes can be used in some applications to maximize flexibility.
• Some probe arrays allow the separation and analysis of individual reaction products from complex mixtures, such as those used in some protocols to identify single nucleotide polymorphisms (SNPs).
• the disclosed genes or gene sets whose expression are related to the diagnosis of a particular neurodegenerative disease (e.g., Alzheimer's or Parkinson's) in a sample (e.g., peripheral blood) are attached to a microarray.
• the chip can be divided into sections each of which contain a variety of regions and alleles for one of the genes in the diagnosis set, and another region of the chip can contain a variety of regions and alleles for another of the genes in the diagnosis set.
• each region of the chip could contain all of the alleles and regions of all of the genes in the set.
• One particularly useful means for assaying the expression levels is through the use of multivariate single channel quantitative RT-PCR. These methods are disclosed in U.S. Patent Applications 60/336,095, filed November 30, 2001, 60/397,475, filed July 19, 2002, 10/496,626, filed March 12, 2001, and 10/096,710, filed March 12, 2002, which are herein incorporated by reference at least for material related to methods and compositions related to multivariate single channel quantitative RT-PCR. Briefly, the method utilizes a PCR-based high-throughput method for simultaneously analyzing the expression of multiple genes.
• the method can use minute quantities of starting material and reach single copy levels of efficiency, for example, where only a single target nucleic acid was available, such as a single copy of transcript from a single target cell. For example, for the analysis of 20 transcripts in triplicate for 4 subjects, less than 1 ⁇ g total RNA per subject is needed.
• the disclosed methods are capable of simultaneously analyzing multiple genes.
• the disclosed methods use gene-specific primers in particular ways.
• the disclosed methods can quantitate multiple genes with the use of a single signal reagent, such as a fluorescent probe.
• the method is useful for obtaining quantitative information about the expression of many different genes in a sample that can contain as little as a single cell. Since the disclosed methods are quantitative, comparisons of the expression patterns at a quantitative level between a variety of different cell states or cell types can be achieved. In general, total RNA can be isolated from the target sample using any isolation procedure.
• RNA can then be used to generate first strand copy DNA (cDNA) using any procedure, for example, using random primers, oligo-dt primers, or random-oligo-dt primers, which are oligo-dt primers coupled on the 3 '-end to short stretches of specific sequence covering all possible combinations, so the primer primes at the junction between the polyA tract and non-poly A tract associated with messenger RNA (mRNA).
• mRNA messenger RNA
• the cDNA is then used as a template in a PCR reaction. This PCR reaction is performed with primer sets, a forward and a reverse primer, that are specific for the expressed genes, which are to be tracked.
• This reaction can contain as many different primer sets as desired, but typically would contain between 5 and 100 different sets of primers, each specific for a single gene or single isoform (including any specific number between 5 and 100). Typically all of the primers will be in about equimolar concentration.
• the PCR is stopped. Typically, in the first round of PCR, if quantitative PCR (real time PCR) was performed, one does not reach the threshold cycle of amplification.
• the disclosed methods in certain embodiments can still work if amplification proceeds for about less than 9, 8, 7, 6, 5, 4, 3, 2, or 1 cycle(s) past the threshold cycle.
• the number of cycles in the first round depends on the amount of starting materials. For example, 20 cycles can be used for single cell experiments.
• the PCR reaction is f ' pafttiMe3 i'hlii3'nSw i ' ' reac ⁇ ion tubes for a (new) second round of PCR. Each of the tubes contains a fraction of the previous PCR reaction mixture which contains all of the products produced from all of the specific primers present in the first PCR mixture.
• the second PCR mixture containing the fraction of the first PCR mixture, typically only one of the specific primer sets or a new primer set is added, in addition to the universal primer which has the molecular beacon attached, and the PCR is performed.
• this second round of PCR is performed using quantitative real time PCR protocols, which, for example, rely on increases in fluorescence at each cycle of PCR through (for example, probes that hybridize to a portion of one of the amplification probes) the release of fluorescence from a quencher sequence while the uniprimer (universal primer) binds to the DNA sequence.
• Fluorescence approaches used in real ⁇ time quantitative PCR are typically based on a fluorescent reporter dye such as SYBR green, FAM, fluorescein, HEX, TET, TAMRA, etc. and a quencher such as DABSYL, Black Hole, etc. When the quencher is separated from the probe during the extension phase of PCR, the fluorescence of the reporter can be measured.
• Systems like Molecular Beacons, Taqman Probes, Scorpion Primers or Sunrise Primers and others use this approach to perform real-time quantitative PCR. Examples of methods and reagents related to real time probes can be found in U.S. Patent Nos.
• a key aspect to understanding the disclosed methods is the combination of a first PCR containing the multiple different primer sets in a batch PCR mixture in which all target gene products or fragments of gene products are amplified with a second PCR panel in which the specific amplification reaction occurs in which a portion of the batch PCR mixture is amplified with specific primer sets. Quantitation is typically achieved by reference to a standard curve that is generated for the complete primer sets or each individual primer set. e) Preparation of protein
• the disclosed methods can involve some level of protein or peptide preparation.
• the protein or peptide preparation step is not required to be performed as part of a contiguous method, but in certain methods the protein or peptide should be prepared ' ! suc ⁇ i tMt?4f l caJ ⁇ - : Be' ' an ': aIylk;e ⁇ , :: b:g", as disclosed herein.
• the protein or peptide preparation step could be performed far removed from the actual analysis steps (e.g., in another laboratory, or at a much earlier time), in many embodiments the protein or peptide isolation and preparation, e.g., electrophoresis, will occur in conjunction with the quantitation steps of the methods; but this is not required.
• the method of protein or peptide preparation can be any method of protein or peptide preparation that produces analyzable protein or peptide.
• the sample cells can be lysed in "crack buffer” (50 mM Tris-HCl (pH, 6.8), 100 mM DTT, 100 ⁇ g/ml PMSF, 2% SDS, 10% glycerol, 1 ⁇ g /ml each of pepstatin A, leupeptin, and aprotinin, and 1 m sodium orthovanadate), and sheared with a 22 gauge needle.
• the protein content of the samples can be estimated using the DC protein assay (BioRad).
• Protein (10-20 ⁇ g) can be resolved using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with 10% SDS. Typically the quantity of protein or peptide obtained can be determined.
• the proteins or peptides can be isolated from any desired cell or cell type and from any organism, including mammals, such as mouse, rat, rabbit, dog, cat, monkey, and human, as well as other non-mammalian animals, such as fish or amphibians, as well as plants and even prokaryotes, such as bacteria.
• Protein expression analysis 92 Li certain embodiments of the disclosed methods, assessing the level of expression of one or more proteins or peptides can be performed.
• the level of protein or peptide expression can be assessed in addition to the nucleic acid analysis disclosed herein, or as an alternative to the nucleic acid analysis. Assessing a level of expression of one or more proteins in a sample can be performed by various techniques known in the art.
• assessing the level of expression can involve analyzing one or more proteins by two-dimensional gel electrophoresis, mass spectroscopy (MS), matrix-assisted laser desorption/ionization-time of fliglit-MS (MALDI- TOF), surface-enhanced laser desorption ionization-time of flight (SELDI-TOF), high performance liquid chromatography (HPLC), fast protein liquid chromatography (FPLC), multidimensional liquid chromatography (LC) followed by tandem mass spectrometry (MS/MS), protein chip expression analysis, gene chip expression analysis, and laser densitometry, including combinations of these techniques, hi another example of a technique for analyzing protein expression levels, one can assay the amount of mRNA that encodes for a particular protein or proteins.
• MS mass spectroscopy
• MALDI- TOF matrix-assisted laser desorption/ionization-time of fliglit-MS
• SELDI-TOF surface-enhanced laser desorption ionization-time of flight
• an antibody or other agent that selectively binds to a protein can be used to detect the amount of that protein expressed in a sample.
• the level of expression of a protein can be measured using methods that include, but are not limited to, Western blot, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescent activated cell sorting (FACS), or a combination thereof.
• antibodies, aptamers, or other ligands that specifically bind to a protein can be affixed to so-called “protein chips” (protein microarrays) and used to measure the level of expression of a protein in a sample.
• immunofluorescence techniques can be used to visually assess the expression level of a protein in a sample, hi immunofluorescence techniques, antibodies that specifically bind to a protein are visualized to indirectly detect the presence of a protein on the cell surface of intact leukocytes, and/or throughout permeabilized leukocytes.
• antibodies is used herein in a broad sense and includes both polyclonal and monoclonal antibodies. In addition to intact immunoglobulin molecules, also included in the term “antibodies” are fragments or polymers of those immunoglobulin molecules, and human or humanized versions of immunoglobulin molecules or fragments thereof.
• Monoclonal antibodies include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, as long as they exhibit the desired antagonistic activity (See, U.S. Patent No. 4,816,567 and Morrison, et al., Proc. Natl. Acad. Sci. U.S.A. 1984;81:6851-6855).
• an antibody to alpha synuclein or a conformer thereof can be used to identify the level of alpha-synuclein or various conformers thereof.
• antibodies to native-alpha synuclein, dopamine-adducted alpha-synuclein, and oligomeric or aggregated alpha- synuclein can be used. These antibodies and methods for their preparation and isolation are disclosed in U.S. Patent Application entitled “Alpha-Synuclein Antibodies and Methods Related Thereto,” filed on July 19, 2005, to Federoff et al. 96.
• Non-antibody ligands that selectively bind to a protein can also be used to detect the presence, the absence, and/or to quantify the expression of a protein.
• ligands can be fluorescently labeled (e.g. conjugated to fluorescent molecule, such as green fluorescent protein (GFP)) or ligands can be radiolabeled.
• Labeled ligands can be contacted with a sample, m2 Kirlklnf W ⁇ idii'gai ⁇ i ⁇ " to ' i protein can be assessed.
• the amount of labeled ligand that binds to proteins in the sample is an indication of the amount of a particular protein present in the sample.
• a protein ligand can be contacted to intact cellular sample to detect the expression level of the protein at the cell surface.
• the integrity of leukocytes in a sample can be compromised by permeabilizing or lysing the cells, and subsequently assessing the amount of labeled ligand that binds to proteins in the sample of lysed leukocytes.
• Labels can be directly or indirectly attached to antibodies or non-antibody ligands.
• Direct labeling includes, for example, attaching a label directly to the antibody or non-antibody ligand.
• Indirect labeling includes, for example, attaching a label to a second or third antibody or non-antibody ligand.
• expression levels of the protein can be indirectly monitored by detecting the expression level of the gene that encodes the protein.
• Methods suitable for detecting and/or quantifying genetic expression include, but are not limited to, Northern blot, RNAse protection analyses, reverse transcription-polymerase chain reaction (RT-PCR), and gene-chip (e.g., nucleotide expression microarray) technologies.
• the level of expression of multiple proteins can be determined simultaneously or nearly simultaneously.
• two-dimensional (2D) gel electrophoresis can be used to simultaneously or nearly simultaneously assess the expression level of thousands of proteins in a sample.
• 2D gel electrophoresis See e.g., Vietor and Huber, Biochim. Biophys. Acta., 1997;1359:187-99, which is incorporated by reference herein for at least its teachings of methods to assess levels of protein expression).
• the disclosed methods can include 2D gel electrophoresis, where a mixture of proteins are prepared from the sample, e.g., by lysing leukocytes and mixing the protein lysate with sample buffer.
• the protein mixture can be loaded onto a gel slab, electrophoresed in two dimensions, and then the gel slab can be dried. After resolution by 2D electrophoresis, expression levels of individual proteins or groups of proteins can be assessed. Protein levels can be assessed by silver staining or Coomassie staining. If the proteins in a sample are labeled, then measuring the amount of label can be used to assess the amount of protein. g) Levels of gene product expression and canonical variables
• the detection of the levels of expression of the target genes, the genes disclosed herein as related to a particular neurodegenerative disease (e.g., Parkinson's and Alzheimer's) - ⁇ ani ⁇ aMetfliy ⁇ tlidil-lifiteilo the presence of a neurodegenerative disease in a sample (e.g., blood) of a subject with the disease, i.e., biomarkers, can occur in any way as disclosed herein.
• a sample e.g., blood
• biomarkers i.e., biomarkers
• any data that is collected can be normalized for general expression levels in the cell. This can be done in variety of ways, for example, by comparing all transcripts to that of /3-actin expression, which is present in all cells. Other methods of normalization can be based on approaches other than expression of any single gene. For quantitative PCR, a standard curve should be attained for each message assayed. These standard curves then become the basis for deriving absolute copy numbers.
• Internal controls include, but are not limited to, ⁇ - actin, GAPDH, tubulin, etc. or external controls such as but not limited to cytoplasmic or nuclear LacZ, agamous, or known labeled cRNAs spiked into each hybridization. Using bio-chip approaches, data normalization can also be obtained through averaging samples of interest to the overall array background.
• a level of expression of a biomarker can be subject to a univariant and/or multivariant canonical analysis to produce a first and/or second canonical variable.
• the univariate tests can be the well known T- test or the N-test.
• One N-test that is suitable for use herein is disclosed in Technical Report 04/01 at http://www.urmc.rochester.edu/smd/biostat/people/techreports.html, which is incorporated by reference herein at least for its teaching of the statistical analysis via the N-test.
• multivariant analysis can be performed using commercially available software, such as SAS/STAT® Software, available from SAS Institute, Inc. (Gary, NC). components analysis can be used, for example. These both deal with methods of analyzing matrices of data.
• the canonical variables consist of a first canonical and a second canonical variable.
• the multivariant analysis can be the essentially non- parametric test for multiple testing inference.
• Such multivariate statistical testing relies on canonical discriminant analysis. This analysis determines the variables (messages) that best distinguish groups and assigns weights to each variable.
• the first canonical variable generally provides the best distinction between groups.
• the second canonical variable operates on the residual variance that remains unaccounted for by canonical variable 1. Additional iterations are possible with diminishing effect.
• Canonical discriminant analysis is equivalent to canonical correlation analysis between the quantitative variables and a set of dummy variables coded from the class variable, hi the following notation the dummy variables can be denoted by y and the quantitative variables by x.
• the total sample covariance matrix for the x and y variables is:
• n t is the number of observations in group t
• S t is the sample covariance matrix for the x variables in group t, the within-class pooled covariance matrix for the x variables is
• the canonical correlations, p;, are the square roots of the eigenvalues, ⁇ , of the following matrix.
• the corresponding eigenvectors are Vj.
• the set of gene products can be any set of genes, such as the ones disclosed herein.
• one set of gene products can correspond to a control sample or group of controls and another set of gene products can correspond to a sample or group of samples with disease.
• the levels of gene products can be inputted as absolute or relative amounts or concentrations.
• the levels can also be signal intensities, for example, from radio- or fluoroanalyses of the gene products.
• a result of the multivariant analysis is a first and/or second canonical variable.
• This first and/or second canonical variable produced from the multivariant analysis can be used, as is disclosed herein, in the disclosed methods as a substitute for or in addition to the level of expression for a biomarker. That is, in some examples disclosed herein, the first and/or second canonical variable obtained from analyzing the levels of expression of one or more biomarkers from a subject can be compared to a reference standard that comprises a first and/or second canonical variable obtained from a multivariant canonical analysis of levels of expression of biomarkers from a control or group of control subjects.
• the range for control values for canonical variable 1 can be from about -0.5 to about -3.1 and the range for AD can be from about 0 to +4.4.
• the range for control values for canonical variable 1 can be from about -4.8 to about -0.1 and the range for AD can be from about +0.1 to about +4.1.
• the range for control values for canonical variable 1 can be from about +2.6 to about -3.1 and the range for AD can be from about +3.0 to about -2.3.
• compositions and methods At the core of the disclosed compositions and methods is the analysis of certain messages that are correlated with a neurodegenerative disease such as Parkinson's and
• these messages can be single messages, but typically classes of messages, and sets of messages will be analyzed because they can provide more accurate assessment than for any one of the genes contained within the class or set by itself.
• Table 4 shows exemplary targets that can be analyzed. Multiple gene products, whether mRNA or protein, analyzed simultaneously, allows a neurodegenerative disease such as Parkinson's or Alzheimer's to be diagnosed.
• one class of genes that are useful in diagnosing a neurodegenerative disease such as Alzheimer's is the class of cell cycle transcripts. These can include, for example, cyclin Dl, cyclin B, cyclin Gl, weel, hTR2, CDC25b, GSK3 beta, and protein kinase C alpha. 120.
• a class of genes that are useful in diagnosing a neurodegenerative disease such as Alzheimer's is the class of inflammatory response transcripts. These can include, for example, C5, Cl inhibitor, IL-17r, IL-8, LIF, TNF-alpha, and IL-IOr.
• a class of genes that are useful in diagnosing a neurodegenerative disease such as Alzheimer's is the class of cell stress transcripts. These can include, for example, Alpha-1 antichymotrypsin, HSP 27, HSP 90, crystalline, GAPDH, ferritin H, ferritin L, cox 1, cox 2, and transferrin.
• any combination or subset of cyclin Dl, cyclin B, cyclin Gl, weel, hTR2, CDC25b, GSK3 beta, protein kinase C alpha, C5, Cl inhibitor, IL- 17r, IL-8, antichymotrypsin, HSP 27, HSP 90, crystalline, GAPDH 3 ferritin H, ferritin L, cox 1, cox 2, and transferrin can be used.
• a class of genes that are useful in diagnosing a neurodegenerative disease such as Parkinson's disease include, for example, HSP60, Dihydrolipoamide dehydrogenase, ER-60 protease, Glucose-6-phosphate dehydrogenase, ATP- synthase beta chain, Annexin I, 14-3-3 epsilon, Prohibitin, Phospoglycerate mutase 1, Apoliporotein AI, Superoxide dismutase, RNA-binding protein regulatory subunit, Chain A thioredoxin peroxidase B, RAS-related protein RAPlB, Tumor rejection antigen, Haptoglobin, Fibrin beta, actin-interacting protein 1 (AIPl), mitogen activated protein kinase I (MAPKI), actin or a fragment thereof, glutaraldehyde-3 -phosphate dehydrogenase (GAPDH), transforming protein RhoA, acidic levothyl,
• genes in the sets or classes there can be at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or 100 different genes or gene products within a set or class.
• one gene can be used for analysis, such as gene products related to alpha- 1 antichymotrypsin, crystalline, and cycloogygenase H
• Table 4 Exemplary targets for neurodegenerative diseases, such as Alzheimer's and Parkinson's, which can be analyzed. General classes of these targets are also provided, though targets can have functions that impact a variety of cell processes other than those identified.
• biomarkers whose level of expression can be assessed and compared to a reference standard for example, include human transformer 2-beta, hTra2-beta, human SAF-b, Mainclone, pht ⁇ , MIF, mainclone interacting factor, ppl7, ESAF, hnRNPG, cd21ike kinases clkl-4. Further examples of biomarkers include those listed in Table 5.
• biomarkers include, but are not limited to, HSP60, Dihydrolipoamide dehydrogenase, ER-60 protease, Glucose-6-phosphate dehydrogenase, ATP- synthase beta chain, Annexin 1, 14-3-3 epsilon, Prohibitin, Phospoglycerate mutase 1, Apoliporotein AI, Superoxide dismutase, RNA-binding protein regulatory subunit, Chain A thioredoxin peroxidase B, RAS-related protein RAPlB, Tumor rejection antigen, Haptoglobin, Fibrin beta, including combinations thereof, hi other examples, suitable biomarkers include, but are not limited to, proteins having a molecular weight (MW) of 27,100 and isoelectric point (pi) of 7.58, a MW of 25,400 and pi of 6.2, and a MW of 27,600 and pi of 5.92.
• MW molecular weight
• pi isoelectric point
• Table 5 Identified proteins that differ between Parkinson's disease patients and control subjects.
• biomarkers whose level of expression can be assessed and compared to a reference standard, as described herein, include actin-interacting protein 1 (AIPl), mitogen activated protein kinase I (MAPKT), actin or a fragment thereof, annexin Al, 14-3-3 protein epsilon, glutaraldehyde-3-phosphate dehydrogenase (GAPDH), transforming protein RhoA, acidic leucine-rich nuclear phosphoprotein 32 family member B (ANP32B or APRIL), peroxiredoxin II, an amyloid precursor protein (APP), ⁇ -secretase, /3-secretase, ⁇ - secretase, A 1 S peptide, Fe65, Tip60, SERCA, PS1/2, nectin-la, or non-amyloid ⁇ component of senile plaque (NACP/ a-synuclein). 3. Comparing levels of expression
• the level (or canonical variable) when the level of expression of a biomarker(s) is assessed (and optionally a first and/or second canonical variable obtained), the level (or canonical variable) can be compared with the level of expression of the biomarker(s) (or canonical variable obtained therefrom) in a reference standard.
• reference standard is meant the level of expression of a particular biomarker(s) from a sample or subject lacking a neurodegenerative disease, at a different stage of a disease, or in the absence of a particular variable such as a therapeutic agent.
• the reference standard can comprise a known amount of biomarker.
• a reference standard can also include the expression level of one or more biomarkers from one or more different samples or subjects as described herein.
• a reference standard can include an assessment of the expression level of one or more biomarkers in a sample from a subject that does not have a neurodegenerative disease, is at a different stage of progression of a neurodegenerative disease, or has not received treatment for a neurodegenerative disease.
• Another exemplary reference ⁇ 'ciyiSOllffe ⁇ a-lisesBiiiielt of the expression level of one or more biomarkers in samples taken from multiple subjects that do not have a neurodegenerative disease, are at a different stage of progression of a neurological disease, or have not received treatment for a neurological disease. 130.
• the control sample or subject can be the same sample or subject to be tested before or after treatment with a therapeutic agent or can be a different sample or subject in the absence of the therapeutic agent.
• a reference standard can be an average expression level calculated from a number of subjects without a particular neurodegenerative disease.
• a reference standard can also include a known control level or value known in the art. In one aspect of the methods disclosed herein, it can be desirable to age-match a reference standard with the subject diagnosed with a neurodegenerative disease.
• a reference standard can also be a first or second canonical variable obtained from a multivariant canonical analysis of levels of expression of a biomarker(s) from a control or group of control subjects.
• each sample can be separately subjected to 2D gel electrophoresis.
• each sample can be differently labeled and both samples can be loaded onto the same 2D gel. See e.g., UnIu et al., Electrophoresis, 1997;18:2071-2077, which is incorporated by reference herein for at least its teachings of methods to assess and compare levels of gene product expression.
• the same gene product or group of gene products in each sample can be identified by the relative position within the pattern of gene products resolved by 2D electrophoresis.
• the expression levels of one or more gene products in a first sample can then be compared to the expression level of the same gene product(s) in the second sample, thereby allowing the identification of a gene product or group of gene products that is expressed differently between the two samples (e.g., a biomarker). This comparison can be made for subjects before and after they are suspected of having a neurodegenerative disease, before and after they begin a therapeutic regimen, and over the course of that regimen. 132.
• the expression level of one or more gene products can be in a single sample as a percentage of total expressed gene products. This assessed level of expression can be compared to a preexisting reference standard, thereby allowing for the ⁇ lntine'atlorrol'gen' ⁇ ' pTOt&cxVthat are differentially expressed in the sample relative to the reference standard.
• Gene products whose expression levels vary from a reference standard can be identified by, for example, extracting those gene products from a 2D gel and employing an identification technology such as mass spectroscopy (MS), which includes techniques such as or matrix-assisted laser desorption/ionization-time of flight-MS (MALDI-TOF).
• MS mass spectroscopy
• MALDI-TOF matrix-assisted laser desorption/ionization-time of flight-MS
• chips e.g., arrays of protein binding antibodies, ligands, or aptamers
• chips can be used to identify gene products that are expressed differently in a sample than in a reference standard. See, e.g., Glokler and Angenendt, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2003;797:229-240. These references are incorporated by reference herein at least for their teachings of methods to assess and compare gene product expression levels.
• differential gene expression causes the expression of one or more gene products to be different in the sample and the reference standard
• these one or more gene products can be further identified using methods that identify differentially expressed gene transcripts, e.g., gene chip (nucleotide expression microarrays) or differential display technologies (e.g. differential display kits from Clontech, Palo Alto, CA or GenHunter, Nashville, TN).
• gene chip nucleotide expression microarrays
• differential display technologies e.g. differential display kits from Clontech, Palo Alto, CA or GenHunter, Nashville, TN.
• an increase in the level of expression of the gene product, as compared to the reference standard can identify the gene product as a biomarker for diagnosing the neurodegenerative disease " , Me ⁇ m- ⁇ f cafk ⁇ fts ⁇ tfl orAlzheimer's disease.
• a decrease in the level of expression of the gene product, as compared to the reference standard can also identify the gene product as a biomarker for diagnosing the neurodegenerative disease.
• a combination of increased gene products and decreased gene products as compared to a reference standard can identify the gene products as biomarkers for diagnosing the neurodegenerative disease.
• Biomarkers identified by the disclosed methods can be used in a variety of other methods. For example, biomarkers can be used to diagnose a particular neurodegenerative disease. In another example, biomarkers can be used monitor the progression of a disease since the level of expression of some biomarkers can become more pronounced (or less pronounced) as a particular neurodegenerative disease progresses, hi yet another example, a biomarker can be used to monitor a subject's response to treatment for a disease. These and other uses are disclosed herein.
• Disclosed are methods of diagnosing a neurodegenerative disease such as Alzheimer's or Parkinson's disease comprising collecting a sample (e.g. blood or leukocytes) from a subject, assaying the expression of a set of genes in the sample, and comparing this expression to a control.
• a sample e.g. blood or leukocytes
• Also disclosed are methods of diagnosing a neurodegenerative disease the method comprising, collecting a blood sample from a subject, assaying the expression of a set of genes in the sample, and comparing this expression to a control.
• Also disclosed are methods of diagnosing a neurodegenerative disease the method comprising, collecting leukocytes from a subject, assaying the expression of a set of genes in the leukocytes, and comparing this expression to a control.
• MMSE Mini-Mental Status Examination
• Disclosed are methods of diagnosing a neurodegenerative disease comprising collecting peripheral blood sample from a subject, lysing erythrocytes contained wlt ⁇ nlhis llnl ⁇ ljSoll ⁇ itli ⁇ llPrlEnaining leukocytes, lysing the leukocytes producing a lysed sample, collecting total nucleic acids in the lysed sample forming a nucleic acid sample, isolating the RNA in the nucleic acid sample, extracting the RNA in the nucleic acid sample, collecting the polyA RNA, and identifying the presence of a set of RNA transcripts. 146.
• Also disclosed are methods of diagnosing a neurodegenerative disease comprising collecting a sample (e.g., a leukocyte sample) from a subject, collecting the mRNA within the sample, hybridizing the mRNA with a collection of nucleic acids, wherein the collection of nucleic acids comprises one or more genes found in Table 4, such as cyclin Dl, cyclin B, cyclin Gl, weel, hTR2, CDC25b, GSK3 beta, and protein kinase C alpha, which are related to cell cycle, C5, Cl inhibitor, IL- 17r, IL-8, LIF, TNF-alpha, and IL-IOr, which are related to inflammatory systems, and Alpha- 1 antichymotrypsin, HSP 27, HSP 90, crystalline, GAPDH, ferritin H, ferritin L, cox 1, cox 2, and transferrin, which are related to cell stress, including any combination thereof.
• a sample e.g., a leukocyte sample
• Disclosed are methods of diagnosing a neurodegenerative disease comprising collecting peripheral blood sample from a subject, lysing erythrocytes contained within this sample, collecting the remaining leukocytes, lysing the leukocytes producing a lysed sample, collecting total nucleic acids in the lysed sample forming a nucleic acid sample, isolating the RNA in the nucleic acid sample, extracting the RNA in the nucleic acid sample, collecting the polyA RNA, and identifying the presence of a set of RNA transcripts. 148.
• Also disclosed are methods of diagnosing a neurodegenerative disease the method comprising collecting a peripheral blood sample from a subject, collecting leukocytes from the peripheral blood sample, wherein collecting the leukocytes comprises lysing erythrocytes in the peripheral blood sample and centrifuging, lysing the leukocytes, collecting a total nucleic acid sample from the lysed leukocytes, wherein the collection of the nucleic acid comprises adsorption of the nucleic acids on magnetic beads, collecting a total RNA sample from the nucleic acid sample, collecting a polyA mRNA sample from the total RNA sample, hybridize the total mRNA sample with a set of diagnostic genes, wherein the set of diagnostic genes comprises one or more genes from Table 4, such as cyclin Dl, cyclin B, cyclin Gl, weel, hTR2, CDC25b, GSK3 beta, and protein kinase C alpha, which are related to cell cycle, C5, Cl inhibitor, IL-17r, IL-8,
• the data can be normalized by normalizing a housekeeping gene such as GapDH, cyclophilin, or actin.
• Other methods include spiking samples, normalizing to the average or sum of signal intensity over the whole array.
• a) Method of Screening for a Therapeutic Agent 150 In yet another aspect, disclosed herein are methods for screening for a therapeutic agent for the treatment of a neurodegenerative disease (e.g., Parkinson's or Alzheimer's disease).
• the disclosed methods comprise contacting a leukocyte or population of leukocytes with the agent to be screened and detecting a level of expression or activity of a biomarker for the neurodegenerative disease.
• a biomarker for the neurodegenerative disease.
• neuronal cells or populations thereof can be used.
• an increase or decrease in the level of expression or activity of the biomarker can indicate a therapeutic agent for the treatment of the neurodegenerative disease.
• the disclosed methods can be utilized to screen agents that are nucleic acids, antibodies, polypeptides, or small molecules, including any therapeutic mixtures or combinations thereof.
• the leukocyte or lysate thereof can be accomplished by any technique.
• the cells or lysate can be submerged or immersed in the agent or solution containing the agent.
• the cells or lysate can be coated or sprayed with the agent or solution containing the agent, hi still another example, the cells or lysate can be contacted with a medium, such as a culture medium, that contains the agent or solution containing the agent.
• the cells or lysate can be infused with the agent or solution containing the agent.
• the particular method of contacting the leukocytes or lysate thereof with the agent to be screened will be readily apparent to one of ordinary skill in the art and will depend on such factors as the size of the sample, the particular agent to be screened, convenience, preference, and the like.
• the biomarker whose level of expression or activity is detected can be one or more genes or proteins that are down-regulated in the neurodegenerative disease. Li this example, when the agent increases the level of expression or activity of the gene or protein biomarkers, this can indicate a therapeutic agent for the treatment of the particular neurodegenerative disease.
• the biomarker can be one or more genes or proteins that are up-regulated in the neurodegenerative disease, hi this example, a therapeutic agent for the treatment of the particular neurodegenerative disease can be indicated when the agent decreases the level of expression or activity of the gene or protein biomarkers. Still further, a
• the neurons can be dopaminergic neurons.
• the disclosed methods can further comprise determining whether the therapeutic agent prevents the development of or slows the progression of a neurodegenerative disease in an animal model of the disease.
• suitable animal models include, but are not limited to, a MPTP model, a 6-OHDA model, a paraquat model, or a rotenone model.
• neurodegenerative disease e.g., Parkinson's or Alzheimer's disease
• the disclosed methods comprise comparing a level of expression or activity of a biomarker for a neurodegenerative disease in a sample comprising leukocytes or a lysate thereof obtained from the subject at multiple time points.
• a neurodegenerative disease e.g., Parkinson's disease
• the disclosed methods can comprise comparing a level of expression or activity of a biomarker for the neurodegenerative disease in a sample comprising leukocytes or a lysate thereof obtained from the subject at multiple time points during treatment of the subject.
• the subject can be as disclosed above (e.g., human). Also, the subject can be asymptomatic or preclinical for neurodegenerative disease at one or more of the multiple time points. In another example, the subject has not received treatment for the neurodegenerative disease at one or more of the multiple time points. 159.
• treatment is meant any medical intervention that the subject received or undergoes for the purpose of curing, preventing, or alleviating the disease.
• Treatment can include, but is not limited to, pharmacological therapy (e.g., the administration of pharmaceuticals), nutritional therapy (e.g., the administration of vitamins, hormones, I l ⁇ tfalMIIlliiitfaii SMI 1 IM; or supplements, or the alteration of diet), physical therapy, surgical treatment, non-pharmacological therapy, behavioral modification, and the like.
• pharmacological therapy e.g., the administration of pharmaceuticals
• nutritional therapy e.g., the administration of vitamins, hormones, I l ⁇ tfalMIIlliiitfaii SMI 1 IM; or supplements, or the alteration of diet
• physical therapy e.g., the administration of vitamins, hormones, I l ⁇ tfalMIIlliiitfaii SMI 1 IM; or supplements, or the alteration of diet
• the subject receives treatment for a neurodegenerative disease at one or more of the multiple time points.
• the subject is treated with a neuroprotective agent at or before one of the multiple time points.
• the subject is treated with a dopamine agonist (e.g., levodopa) at one or more of the multiple time points, hi another specific example, the subject is treated with a neuroprotective agent at one or more of the multiple time points.
• a dopamine agonist e.g., levodopa
• neuroprotective agents which can be used to treat a subject include, but are not limited to, an acetylcholinesterase inhibitor, a glutamatergic receptor antagonist, kinase inhibitors, HDAC inhibitors, anti-flammatory agents, divalproex sodium, or any combination thereof.
• neuroprotective agents can include, but are not limited to, Obidoxime Chloride; Pralidoxime Chloride; Pralidoxime Iodide; Pralidoxime Mesylate,
• Alverinc Citrate Anisotropine Methylbromide; Atropine; Atropine Oxide Hydrochloride;
• Tofenacin Hydrochloride Toquizine; Triampyzine Sulfate; Trihexyphenidyl Hydrochloride; Tropicamide.
• Further examples include, but are not limited to, Albutoin; Ameltolide; Atolide;
• anti-imflammatory agents include, but are not limited to, Alclofenac; Alclometasone Dipropionate; Algestone Acetonide; Alpha Amylase; Amcinafal; Amcinafide; Amfenac Sodium; Amiprilose Hydrochloride; Anakinra; Anirolac; Anitrazafen; Apazone; Balsalazide Disodium; Bendazac; Benoxaprofen; Benzydamine Hydrochloride; Bromelains; Broperamole; Budesonide; Carprofen; Cicloprofen; Cintazone; Cliprofen; Clobetasol Propionate; Clobetasone Butyrate; Clopirac; Cloticasone Propionate; Cormethasone Acetate; Cortodoxone
• the subject can be treated with a non-pharmacological treatment, i.e., treatments that do not primarily involve drugs.
• non-pharmacological drugs include, but are not limited to, brain stimulation, which is typically used in PD, ventricular shunt and transposition of omentum, which has been used in AD.
• brain stimulation which is typically used in PD
• ventricular shunt and transposition of omentum, which has been used in AD.
• Ifei ⁇ bjeffiSyfci' € ⁇ fteated by behavioral modification Still further examples of treatments involve gene therapy, transplants, and stem cells.
• a level of biomarker(s) expression or activity assessed at one point in time can be the same as the level assessed at another point in time. This can indicate that the particular neurodegenerative disease has not changed (e.g., the disease has not gotten worse or better).
• a level of biomarker(s) expression or activity at an earlier point in time can be more or less than the level at a later point in time. This can indicate that the neurodegenerative disease is progressing.
• a biomarker's level of expression has been previously shown to increase from an earlier point in time to a later point in time and to correlate with (a) worsening or (b) improvement of the symptoms of a disease, then a lower amount of biomarker present in the earlier sample relative to the later sample can be considered to be an indication that the subject's condition is (a) worsening or (b) improving, respectively.
• biomarker's level of expression has been shown to decrease from an earlier point in time to a later point in time and to correlate with (a) worsening or (b) improvement of the symptoms of a disease
• a higher amount of biomarker present in the earlier sample relative to the later sample can be an indication that the subject's condition is (a) worsening or (b) improving, respectively.
• a combination of biomarkers where some biomarkers in the combination increase from an earlier point in time to a later point in time during disease progression and other biomarkers decrease, can be used. 163.
• the level of a biomarker can be correlated with a worsening or an improvement in one or more symptoms of a neurodegenerative disease in response to the therapy.
• Gene product(s) whose expression levels are different between a sample taken prior to treatment or at an earlier point in time during treatment and a sample taken at a later point in time during treatment or after treatment can identify a biomarker for the response of a subject to a treatment for a neurodegenerative disease.
• a difference in a level of expression or activity of a biomarker between various samples can be indicative of the subject's responsiveness to the administered treatment for the neurodegenerative disease. If a biomarker's expression has been previously shown to increase in subjects that (a) respond or (b) fail to respond to the treatment for a neurodegenerative disease, then a larger amount of biomarker in a later sample relative to an earlier sample can be an indication that the subject is (a) responding or (b) not responding, respectively, to the treatment.
• a biomarker's expression has been previously shown to decrease in subjects that (a) respond or (b) fail to respond to a treatment for a CnIur ⁇ ilfe ⁇ iiliirEti ⁇ di3is ⁇ s' ⁇ - :t ⁇ hfen a smaller amount of biomarker in a later sample relative to an earlier sample can be considered to be an indication that the subject is (a) responding or (b) not responding, respectively to the treatment.
• biomarkers are used and one or more biomarkers have been previously shown to decrease in subjects that (a) respond or (b) fail to respond to a treatment for a neurodegenerative disease and one or more other biomarkers have been previously shown to increase, then a change in the amount of biomarkers in the combination of biomarkers from a later sample relative to an earlier sample can be considered to be an indication that the subject is (a) responding or (b) not responding, respectively to the treatment.
• a neurodegenerative disease e.g., Parkinson's or Alzheimer's disease
• the disclosed methods comprise determining a level of expression or activity of a biomarker for a neurodegenerative disease from a sample obtained from the test subject, wherein the sample comprises leukocytes or a lysate thereof; and correlating the level of expression or activity level of the biomarker determined for the test subject with the levels for a reference subject.
• the method can further comprise determining the level of the biomarker(s) from a population of reference subjects diagnosed with the neurodegenerative disease and/or from a population of reference subjects without the neurodegenerative disease, hi the disclosed methods, a correlation between levels for a reference population without the neurodegenerative disease and the levels for the test subject can identify a low risk for the particular neurodegenerative disease in the test subject. Also, a correlation between the levels determined for the reference population with the neurodegenerative disease and the levels for the test subject can identify a high risk for the neurodegenerative disease in the test subject.
• correlation is meant any relationship between data. For example, a correlation can be determined through a statistical analysis of the levels of biomarker expression or activity (e.g., standard deviation, degree of confidence, etc.). A correlation can also be an empirical determination based on the levels of biomarker expression or activity.
• Gene product data e.g., transcript and/or proteomic data
• each subject sample can be run in triplicate on 2D gels (e.g., 52 subjects x 3 gels equals 156 gels). Averaged spot intensities can then be used for further analysis.
• Gender basic clinical diagnosis, and clinical indices can CWiriHJiilllik'Mi'
• Primary comparisons using simple univariate statistical methods such as two-sample t-tests can proceed to identify those proteins whose expression in leukocytes are different between disease subjects and the control group.
• Proteomic data from 2D gel electrophoresis and MALDI-TOF mass spectroscopy can be first analyzed using the statistical tools, including t-tests and ANOVAs, contained within the Progenesis Workstation Image Analysis and Informatics software program (Nonlinear USA, Inc.; Durham, NC).
• a step-down multivariate resampling algorithm can be used to address the multiplicity of tests, as disclosed in Troendle, A permutational step-up method of testing multiple outcomes, Biometrics, 1996;52:846-859, which is incorporated by reference herein at least for its teachings of statistical methods.
• multivariate statistical methods can be more appropriate and powerful in all classifications and associations being considered in such studies.
• Canonical discriminant analysis can be performed to use the profiling of all gene products together for the disclosed methods.
• Logistic discrimination between groups based on multivariate observations can be used since it generally out-performs the normal-theory-based linear discriminant analysis (see McLachlan, Discriminant analysis and statistical pattern recognition, Wiley, New York, 1992, which is incorporated by reference herein at least for its teaching of statistical methods).
• linear models and generalized linear models e.g., those disclosed in Nelder and McCullagh, Generalized Linear Models, CRC Press, Boca Raton, FL, 1999, which is incorporated by reference herein at least for its teaching of linear models
• linear models can be fitted to profile proteins differentially expressed in the neurodegenerative disease and non-neurodegenerative disease leukocytes and to identify those proteins whose expression changes are related to the severity of disease.
• These models can also take in consideration the confounding issues of some clinical factors.
• Missing values can be handled as suggested by Little and Little (Applications of Modern Missing Data Methods, CRC Press, Boca Raton, FL, 2002, which is incorporated by reference herein at least for its teaching of statistical methods), hi cases of unexpected complication of data analysis, the skill artisan can pursue appropriate statistical methods and even develop and program statistical methods to serve these specific aims, including the use of nonparanietric empirical Bayesian analysis proposed by Efron and Tibshirani, Empirical bayes methods and false discovery rates for microarrays, Genet Epidemiol. 2002;23:70-86, which is incorporated by reference herein at least for its teaching of statistical methods. !»i
• a neurodegenerative disease e.g., Parkinson's or Alzheimer's disease
• the disclosed methods comprise assessing a level of expression or activity of one or more selected biomarker(s) in a sample comprising leukocytes or a lysate thereof from the test subject and comparing the level of expression or activity of the selected biomarker(s) to a reference standard that indicates the level of expression or activity of the selected biomarker(s) in one or more populations of neuropathologic control subjects with one or more neuropathological control diseases, hi the disclosed methods, a difference or similarity between the level of expression or activity of the selected biomarker(s) and the reference standard can indicate a differential diagnosis of one neurodegenerative as compared to the neuropathological control diseases.
• differentiated is meant to identify the presence of one particular disease in a subject and/or identify the absence of another disease in a subject. The phrase also means to distinguish one particular disease from another disease or from the absence of a disease. “Differentially diagnose” is also used herein to mean to identify a particular stage of one disease, to identify the risk of developing a particular disease, or to identify a prognosis of a particular disease.
• neuropathologic control subject is meant a subject (e.g., human) or group of subjects that have one or more neurodegenerative diseases, as described herein.
• the neuropathologic control subject can be one or more subjects with Alzheimer's disease, frontal-temporal dementia, mild cognitive impairment, and Parkinson's disease, plus disorders that comprise additional symptoms (e.g., multiple system atrophy, corticobasal ganglionic degeneration, Parkinson's disease with Alzheimer's).
• the neuropathologic control subject can also be a subject or group of subjects that does not have a particular disease.
• neuropathologic control subject can also be a subject or group of subjects that has a particular risk or predisposition of developing a disease.
• test subject and the reference populations can be age or sex matched or both.
• Biomarkers for a neurodegenerative disease such as Parkinson's or Alzheimer's disease, can be identified by the methods disclosed herein.
• methods for identifying a biomarker for a particular neurodegenerative disease can comprise assessing a level
• an increase or decrease in the level of expression of the gene products, as compared to the reference standard, can identify the gene products as biomarkers for the particular neurodegenerative disease.
• the same biomarkers can be used for diagnosing, monitoring disease progression, and/or monitoring the response of a subject to a therapy for a disease, are the same biomarker.
• the altered expression of the biomarker (under the conditions of the two or more different uses) can reflect the same fundamental biochemical and metabolic pathways that underlie the pathology of the particular neurodegenerative disease.
• the same biological pathways can cause both a gene product to be expressed at a particular level in a healthy subject that is free of the neurodegenerative disease and the same gene product to be expressed at a similar level in a in a subject responding to a treatment for the disease. 175.
• biomarkers can be a due to changes in biochemical/metabolic pathways that underlie the pathology of a disease
• these biomarkers also represent therapeutic targets. If a change in expression of a biomarker causes one or more symptoms of a neurodegenerative disease, then the biomarker can be a therapeutic target.
• Therapeutic targets can be used in methods for discovering compounds that modulate the expression or activity of one or more candidate biomarkers and/or improve one or more symptoms of the neurodegenerative disease (i.e., candidate therapeutic agents).
• AD Alzheimer's disease
• Neuropathological and neurobiological changes associated with this slow progression of clinical symptoms include accumulation of amyloid plaques and neurofibrillary tangles (NFTs) (Gearing M, et al, The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology. 1995;45(3 Pt l):461-466) gliosis (Unger JW, Microscopy Res.
• NFTs neurofibrillary tangles
• genes that are related to synaptic structure and function and the neuronal cytoskeleton include decreased expression of selected genes that are related to synaptic structure and function and the neuronal cytoskeleton (Ginsberg SD, et al., Annals of Neurology, 2000;48(l):77-87; Yao P, et al., J. Neuroscience, 1998;18(7):2399-2411).
• Other classes of genes whose expression is altered in AD include those related to the cell cycle (Arendt T,
• leukocytes Wakutani Y, et al., Dementia, 1995;6(6):301-305
• monocytes Jung SS, et al., Neurobiology of Aging, 1999;20(3):249-257
• epithelial cells Schomitz A, et al., Histochemistry & Cell Biology, 2002;117(2):171-180
• Multivariate analysis of profiles of expression of multiple gene products (messages) by single neurons or homogenates from postmortem human brain can be used to distinguish neurodegenerative disease (e.g., Parkinson's and Alzheimer's disease) from control samples (Cheetham JE, et al., J. Neuroscience Methods, 1997;77(l),:43-48, Chow N, et al., Proc. Natl. Acad. Sci. U.S.A., 1998;95:9620-9625).
• neurodegenerative disease e.g., Parkinson's and Alzheimer's disease
• data relating to using multiple genes to diagnose of neurodegenerative disease is obtained from samples such as peripheral blood and blood leukocytes.
• samples such as peripheral blood and blood leukocytes.
• varying sets of genes are used and genes related to the inflammatory response as well as the cell cycle are predicative.
• Blood was drawn from patients diagnosed in our Alzheimer's Disease Center as having probable (mild) AD ied control sample.
• Message was extracted from peripheral blood leukocytes and amplified (Eberwine J, et al., PNAS U.S.A. 1992;89(7):3010-3014). The expression level of selected messages was then quantified. Multivariate statistical analyses differentiated Alzheimer's and control white blood cells.
• homology and identity mean the same thing as similarity.
• the use of the word homology is used between two non-natural sequences it is understood that this is not necessarily indicating an evolutionary relationship between these two sequences, but rather is looking at the similarity or relatedness between their nucleic acid sequences.
• Many of the methods for determining homology between two evolutionarily related molecules are routinely applied to any two or more nucleic acids or proteins for the purpose of measuring sequence similarity regardless of whether they are evolutionarily related or not.
• variants of genes and proteins herein disclosed typically have at least, about 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent homology to the stated sequence or the native sequence.
• the homology can be calculated after aligning the two sequences so that the homology is at its highest level.
• Another way of calculating homology can be performed by published algorithms. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman, Adv. Appl. Math, 1981;2:482, by the homology alignment algorithm of Needleman and Wunsch, J. MoI. Biol., 1970;48:443, by the search for similarity method of Pearson and Lipman, Proc. Natl. Acad. Sci. U.S.A., 1988;85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wl), or by inspection.
• a sequence recited as having a particular percent homology to another sequence refers to sequences that have the recited homology as calculated by any one or more of the calculation methods described above.
• a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using the Zuker calculation method even if the first sequence does not have 80 percent homology to the second sequence as calculated by any of the other calculation methods.
• a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using both the Zuker calculation method and the Pearson and Lipman calculation method even if the first sequence does not have 80 percent homology to the second sequence as calculated by the Smith and Waterman calculation method, the Needleman and Wunsch calculation method, the Jaeger calculation methods, or any of the other calculation methods.
• a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using each of calculation methods (although, in practice, the different calculation methods will often result in different calculated homology percentages).
• hybridization typically means a sequence driven interaction between at least two nucleic acid molecules, such as a primer or a probe and a gene.
• Sequence driven interaction means an interaction that occurs between two nucleotides or nucleotide analogs or nucleotide derivatives in a nucleotide specific manner. For example, G interacting with C or A interacting with T are sequence driven interactions. Typically sequence driven interactions occur on the Watson-Crick face or Hoogsteen face of the nucleotide.
• the hybridization of two nucleic acids is affected by a number of conditions and parameters known to those of skill in the art. For -GSSk ⁇ i j!ilPsit-c6nein#aiolis, pH, and temperature of the reaction all affect whether two nucleic acid molecules will hybridize.
• selective hybridization conditions can be defined as stringent hybridization conditions.
• stringency of hybridization is controlled by both temperature and salt concentration of either or both of the hybridization and washing steps.
• the conditions of hybridization to achieve selective hybridization may involve hybridization in high ionic strength solution (6X SSC or 6X SSPE) at a temperature that is about 12-25°C below the T m (the melting temperature at which half of the molecules dissociate from their hybridization partners) followed by washing at a combination of temperature and salt concentration chosen so that the washing temperature is about 5°C to about 20°C below the T m .
• the temperature and salt conditions are readily determined empirically in preliminary experiments in which samples of reference DNA immobilized on filters are hybridized to a labeled nucleic acid of interest and then washed under conditions of different stringencies. Hybridization temperatures are typically higher for DNA- RNA and RNA-RNA hybridizations. The conditions can be used as described above to achieve stringency, or as is known in the art. (Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N. Y., 1989; Kunkel, et al. Methods Enzymol., 1987;154:367, which is herein incorporated by reference for material at least related to hybridization of nucleic acids).
• a preferable stringent hybridization condition for a DNA:DNA hybridization can be at about 68°C (in aqueous solution) in 6X SSC or 6X SSPE followed by washing at 68 0 C.
• Stringency of hybridization and washing if desired, can be reduced accordingly as the degree of complementarity desired is decreased, and further, depending upon the G-C or A-T richness of any area wherein variability is searched for.
• stringency of hybridization and washing if desired, can be increased accordingly as homology desired is increased, and further, depending upon the G-C or A-T richness of any area wherein high homology is desired, all as known in the art.
• selective hybridization conditions are by looking at the amount (percentage) of one of the nucleic acids bound to the other nucleic acid. For example, in some embodiments selective hybridization conditions would be when at least about, 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 percent of the limiting nucleic acid is bound to the non-limiting nucleic acid.
• the non-limiting primer is in for example, 10 or 100 or 1000 fold excess.
• This type of assay can where both the limiting and non-limiting primer are for example, 10 fold or 100 fold or 1000 fold below their k d , or where only one of the nucleic acid molecules is 10 fold or 100 fold or 1000 fold or where one or both nucleic acid molecules are above their k d .
• Another way to define selective hybridization is by looking at the percentage of primer that gets enzymatically manipulated under conditions where hybridization is required to promote the desired enzymatic manipulation.
• selective hybridization conditions would be when at least about, 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 percent of the primer is enzymatically manipulated under conditions which promote the enzymatic manipulation, for example if the enzymatic manipulation is DNA extension, then selective hybridization conditions would be when at least about 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 percent of the primer molecules are extended.
• Preferred conditions also include those suggested
• nucleic acid based there are a variety of molecules disclosed herein that are nucleic acid based, including, for example, the nucleic acids that encode, for example, any of the genes disclosed herein as being associated with the onset or progression of a neurodegenerative disease (e.g., Parkinson's and Alzheimer's disease), as well as any other proteins disclosed herein, as well as various functional nucleic acids.
• the disclosed nucleic acids are made up of for example, nucleotides, nucleotide analogs, or nucleotide substitutes. Non-limiting examples of these and ⁇ olhor'tt&ldEttis-'aiiilis'bltllel:- herein.
• the expressed mRNA will typically be made up of A, C, G, and U.
• an antisense molecule is introduced into a cell or cell environment through for example exogenous delivery it is advantageous that the antisense molecule be made up of nucleotide analogs that reduce the degradation of the antisense molecule in the cellular environment.
• a nucleotide is a molecule that contains a base moiety, a sugar moiety and a phosphate moiety. Nucleotides can be linked together through their phosphate moieties and sugar moieties creating an internucleoside linkage.
• the base moiety of a nucleotide can be adenine-9-yl (A), cytosine-1-yl (C), guanine-9-yl (G), uraciM-yl (U), and thymin-1-yl (T).
• the sugar moiety of a nucleotide is a ribose or a deoxyribose.
• the phosphate moiety of a nucleotide is pentavalent phosphate.
• a non-limiting example of a nucleotide would be 3'-AMP (3'- adenosine monophosphate) or 5'-GMP (5'-guanosine monophosphate).
• a nucleotide analog is a nucleotide which contains some type of modification to either the base, sugar, or phosphate moieties. Modifications to nucleotides are well known in the art and would include for example, 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, and 2-aminoadenine as well as modifications at the sugar or phosphate moieties.
• 5-methylcytosine (5-me-C)
• 5-hydroxymethyl cytosine 5-hydroxymethyl cytosine
• xanthine xanthine
• hypoxanthine hypoxanthine
• 2-aminoadenine as well as modifications at the sugar or phosphate moieties.
• Nucleotide substitutes are molecules having similar functional properties to nucleotides, but which do not contain a phosphate moiety, such as peptide nucleic acid (PNA). Nucleotide substitutes are molecules that will recognize nucleic acids in a Watson-Crick or Hoogsteen manner, but which are linked together through a moiety other than a phosphate moiety. Nucleotide substitutes are able to conform to a double helix type structure when interacting with the appropriate target nucleic acid.
• PNA peptide nucleic acid
• conjugates can be link other types of molecules to nucleotides or nucleotide analogs to enhance for example, cellular uptake.
• Conjugates can be chemically linked to the nucleotide or nucleotide analogs.
• conjugates include but are not limited to lipid moieties such as a cholesterol moiety.
• a Watson-Crick interaction is at least one interaction with the Watson-Crick face of a nucleotide, nucleotide analog, or nucleotide substitute.
• the Watson-Crick face of a nucleotide, nucleotide analog, or nucleotide substitute includes the C2, Nl, and C6 positions of a analog, or nucleotide substitute and the C2, N3, C4 positions of a pyrimidine based nucleotide, nucleotide analog, or nucleotide substitute.
• a Hoogsteen interaction is the interaction that takes place on the Hoogsteen face of a nucleotide or nucleotide analog, which is exposed in the major groove of duplex DNA.
• the Hoogsteen face includes the N7 position and reactive groups (NH2 or O) at the C6 position of purine nucleotides.
• compositions including primers and probes, which are capable of interacting with the genes disclosed herein.
• the primers are used to support DNA amplification reactions.
• the primers will be capable of being extended in a sequence specific manner.
• Extension of a primer in a sequence specific manner includes any methods wherein the sequence and/or composition of the nucleic acid molecule to which the primer is hybridized or otherwise associated directs or influences the composition or sequence of the product produced by the extension of the primer.
• Extension of the primer in a sequence specific manner therefore includes, but is not limited to, PCR, DNA sequencing, DNA extension, DNA polymerization, RNA transcription, or reverse transcription. Techniques and conditions that amplify the primer in a sequence specific manner are preferred.
• the primers are used for the DNA amplification reactions, such as PCR or direct sequencing. It is understood that in certain embodiments the primers can also be extended using non-enzymatic techniques, where for example, the nucleotides or oligonucleotides used to extend the primer are modified such that they will chemically react to extend the primer in a sequence specific manner. Typically the disclosed primers hybridize with the nucleic acid or region of the nucleic acid or they hybridize with the complement of the nucleic acid or complement of a region of the nucleic acid. 201. The size of the primers or probes for interaction with the transcripts listed in
• transcripts related to cell cycle such as cyclin Dl, cyclin B, cyclin Gl, weel, hTR2, CDC25b, GSK3 beta, and protein kinase C alpha
• transcripts related to inflammatory systems such as C5, Cl inhibitor, IL-17r, IL-8, LIF, TNF-alpha, and EL-IOr 5
• transcripts related to cell stress such as Alpha-1 antichymotrypsin, HSP 27, HSP 90, crystalline, GAPDH, ferritin H, ferritin L, cox 1, cox 2, and transferrin, and transcripts of proteins listed in Tables 5 and 6.
• the primers or probes can be any size that supports the desired enzymatic manipulation of the primer, such as DNA amplification or the simple hybridization of the probe or primer.
• a primer or probe for the genes listed in Table 4 such as cyclin Dl, cyclin B, cyclin Gl, weel, hTR2, CDC25b, GSK3 beta, and protein kinase C alpha, which are related to cell cycle, C5, Cl inhibitor, IL-17r, IL-8, LIF, TNF-alpha, and IL-IOr, which are related to inflammatory systems, and Alpha- 1 antichymotrypsin, HSP 27, HSP 90, crystalline, GAPDH, ferritin H, ferritin L, cox 1, cox 2, and transferrin, which are related to cell stress, and genes of proteins listed in Tables 5 and 6, can be less than or equal to 6, 7, 8, 9, 10, 11, 12 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36,
• the primers and probes are designed such that they are outside primers whose nearest point of interaction with the genes found in Table 4, such as cyclin Dl, cyclin B, cyclin Gl, weel, hTR2, CDC25b, GSK3 beta, and protein kinase C alpha, which are related to cell cycle, C5, Cl inhibitor, IL-17r, IL-8, LIF, TNF-alpha, and IL-IOr, which are related to inflammatory systems, and Alpha- 1 antichymotrypsin, HSP 27, HSP 90, crystalline, GAPDH, ferritin H, ferritin L, cox 1, cox 2, and transferrin, which are related to cell stress, and genes of proteins listed in Tables 5 and 6, is within 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37,
• the primers and probes are designed such that they are outside primers whose nearest point of interaction with the genes listed in Table 4, such as cyclin Dl, cyclin B, cyclin Gl, weel, hTR2, CDC25b, GSK3 beta, protein kinase C alpha, C5, Cl inhibitor, IL-17r, IL-8, LIF, TNF-alpha, and IL-IOr, Alpha-1 antichymotrypsin, HSP 27, HSP 90, crystalline, GAPDH, ferritin H, ferritin L, cox 1, cox 2, and transferrin, and genes of proteins listed in Tables 5 and 6, is at least 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57
• this product is at least 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 550, 600, 650, 700.
• the product is less than or equal to 20, 21, 22, 23, 24, 25,
• Functional nucleic acids are nucleic acid molecules that have a specific function, such as binding a target molecule or catalyzing a specific reaction.
• Functional nucleic acid molecules can be divided into the following categories, which are not meant to be limiting.
• functional nucleic acids include antisense molecules, aptamers, ribozymes, triplex forming molecules, and external guide sequences.
• the functional nucleic acid molecules can act as affectors, inhibitors, modulators, and stimulators of a specific activity possessed by a target molecule, or the functional nucleic acid molecules can possess a de novo activity independent of any other molecules.
• Functional nucleic acid molecules can interact with any macromolecule, such as DNA, RNA, polypeptides, or carbohydrate chains.
• functional nucleic acids can interact with the mRNA of the genes listed in Table 4, such as cyclin Dl, cyclin B, cyclin Gl, weel, hTR2, CDC25b, GSK3 beta, protein kinase C alpha, C5, Cl inhibitor, IL-17r, IL-8, LIF, TNF- alpha, and IL-IOr, Alpha-1 antichymotrypsin, HSP 27, HSP 90, crystalline, GAPDH, ferritin H, ferritin L, cox 1, cox 2, and transferrin, and genes of proteins listed in Tables 5 and 6, or the genomic DNA of the genes listed in Table 4, such as cyclin Dl, cyclin B, cyclin Gl, weel, hTR2, CDC25b, GSK3 beta, protein kinase C alpha, C5, Cl inhibitor, IL-17r,
• nucleic acids are designed to interact with other nucleic acids based on sequence homology between the target molecule and the functional nucleic acid molecule, m other situations, the specific recognition between the functional nucleic acid molecule and the target molecule is not based on sequence homology between the functional nucleic acid molecule and the target molecule, but rather is based on the formation of tertiary structure that allows specific recognition to take place.
• Antisense molecules are designed to interact with a target nucleic acid molecule through either canonical or non-canonical base pairing. The interaction of the antisense molecule and the target molecule is designed to promote the destruction of the target molecule through, for example, RNAseH mediated RNA-DNA hybrid degradation. Alternatively the antisense molecule is designed to interrupt a processing function that normally would take place on the target molecule, such as transcription or replication. Antisense molecules can be designed based on the sequence of the target molecule. Numerous methods for optimization of antisense efficiency by finding the most accessible regions of the target molecule exist. Exemplary methods would be in vitro selection experiments and DNA modification studies using DMS and DEPC.
• antisense molecules bind the target molecule with a dissociation constant (kj) less than or equal to 10 "6 , 10 "8 , 10 "10 , or 10 "12 .
• kj dissociation constant
• Patents 5,135,917, 5,294,533, 5,627,158, 5,641,754, 5,691,317, 5,780,607, 5,786,138, 5,849,903, 5,856,103, 5,919,772, 5,955,590, 5,990,088, 5,994,320, 5,998,602, 6,005,095, 6,007,995, 6,013,522, 6,017,898, 6,018,042, 6,025,198, 6,033,910, 6,040,296, 6,046,004, 6,046,319, and 6,057,437.
• Aptamers are molecules that interact with a target molecule, preferably in a specific way.
• aptamers are small nucleic acids ranging from 15-50 bases in length that fold into defined secondary and tertiary structures, such as stem-loops or G-quartets.
• Aptamers can bind small molecules, such as ATP (U.S. Patent No. 5,631,146) and theophiline (U.S. Patent No. 5,580,737), as well as large molecules, such as reverse transcriptase (United States patent ' lB(f9?M6fUlfM(i ⁇ Mfi ⁇ khB ⁇ .S. Patent No. 5,543,293).
• Aptamers can bind very tightly with k d S from the target molecule of less than 10 "12 M. It is preferred that the aptamers bind the target molecule with a k d less than 10 "6 , 10 ⁇ 8 , 10 '10 , or 10 "12 . Aptamers can bind the target molecule with a very high degree of specificity. For example, aptamers have been isolated that have greater than a 10000 fold difference in binding affinities between the target molecule and another molecule that differ at only a single position on the molecule (U.S. Patent No. 5,543,293).
• the aptamer have a k d with the target molecule at least 10, 100, 1000, 10,000, or 100,000 fold lower than the k d with a background binding molecule. It is preferred when doing the comparison for a polypeptide for example, that the background molecule be a different polypeptide.
• aptamers of the genes listed in Table 4 such as cyclin Dl, cyclin B, cyclin Gl, weel, hTR2, CDC25b, GSK3 beta, protein kinase C alpha, C5, Cl inhibitor, IL- 17r, IL-8, LIF, TNF-alpha, and EL-IOr, Alpha- 1 antichymotrypsin, HSP 27, HSP 90, crystalline, GAPDH, ferritin H, ferritin L, cox 1, cox 2, and transferrin, or genes of proteins listed in Tables 5 and 6, the background protein could be serum albumin.
• the background protein could be serum albumin.
• Ribozymes are nucleic acid molecules that are capable of catalyzing a chemical reaction, either intramolecularly or intermolecularly.
• Ribozymes are thus catalytic nucleic acid. It is preferred that the ribozymes catalyze intermolecular reactions. There are a number of different types of ribozymes that catalyze nuclease or nucleic acid polymerase type reactions which are based on ribozymes found in natural systems, such as hammerhead ribozymes, (for example, but not limited to, the following U.S. Patent Nos.
• ribozymes cleave RNA or DNA substrates, and more preferably cleave RNA substrates. Ribozymes typically cleave nucleic acid substrates through recognition and binding of the target substrate with subsequent cleavage. This recognition is often based mostly on canonical or non- canonical base pair interactions. This property makes ribozymes particularly good candidates for target specific cleavage of nucleic acids because recognition of the target substrate is based on the target substrates sequence. Representative examples of how to make and use ribozymes to catalyze a variety of different reactions can be found in the following non-limiting list of U.S. Patent Nos.
• Triplex forming functional nucleic acid molecules are molecules that can interact with either double-stranded or single-stranded nucleic acid.
• triplex molecules When triplex molecules interact with a target region, a structure called a triplex is formed, in which there are three strands of DNA forming a complex dependant on both Watson-Crick and Hoogsteen base-pairing. Triplex molecules are preferred because they can bind target regions with high affinity and specificity. It is preferred that the triplex forming molecules bind the target molecule with a k d less than 10 '6 , 10 '8 , 10 "10 , or 10 '12 .
• EGSs External guide sequences
• RNAse P RNAse P
• EGSs can be designed to specifically target a RNA molecule of choice.
• RNAse P aids in processing transfer RNA (tRNA) within a cell.
• Bacterial RNAse P can be recruited to cleave virtually any RNA sequence by using an EGS that causes the target RNA:EGS complex to mimic the natural tRNA substrate. (WO 92/03566 by Yale, and Forster and Altman, Science, 1990;238:407-409).
• RNAse P-directed cleavage of RNA can be utilized to cleave desired targets within eukaryotic cells.
• compositions that are amino acid based such as proteins, peptides, and polypeptides.
• protein amino-acid based polymer
• amino-acid based polymer including variants, derivatives, and modifications, as described herein and as are well understood by those of skill in the art.
• Amino-acid sequence modifications typically fall into one or more of three classes: substitutional, insertional, or deletional variants. Insertions include amino and/or carboxyl terminal fusions as well as intrasequence insertions of single or multiple amino acid residues. Insertions ordinarily will be smaller insertions than those of amino or carboxyl terminal fusions, for example, on the order of one to four residues.
• HSP60 Dihydrolipoamide dehydrogenase, ER-60 protease, Glucose-6-phosphate dehydrogenase, ATP-synthase beta chain, Annexin I, 14-3-3 protein epsilon, Prohibitin, Phospoglycerate mutase 1, Apoliporotein AI, Superoxide dismutase, RNA-binding protein regulatory subunit, Chain A thioredoxin peroxidase B, RAS-related protein RAPlB, Tumor rejection antigen, Haptoglobin, Fibrin beta, actin-interacting protein 1 (AIPl), mitogen activated protein kinase I (MAPKI), actin or a fragment thereof, glutaraldehyde-3-phosphate dehydrogenase (GAPDH), transforming protein RhoA, acidic leucine-rich nuclear phosphoprotein 32 family member B (ANP32B or APRIL), peroxiredoxin ⁇ , an am
• neurodegenerative diseases such as the genes listed in Table 4, such as hTR2, CDC25b, GSK3 beta, protein kinase C alpha, C5, Cl inhibitor, IL- 17r, IL-8, LIF, TNF-alpha, and IL-IOr, Alpha- 1 antichymotrypsin, HSP 27, HSP 90, crystalline, GAPDH, ferritin H, ferritin L, cox 1, cox 2, and transferrin.
• neurodegenerative diseases e.g., Parkinson's and Alzheimer's
• variants of the disclosed diagnostic and prognostic genes such as the genes listed in Table 4 (e.g., cyclin Dl, cyclin B, cyclin Gl, weel, hTR2, CDC25b, GSK3 beta, protein kinase C alpha, C5, Cl inhibitor, IL-17r, IL-8, LIF, TNF-alpha, and IL-IOr, Alpha-1 antichymotrypsin, HSP 27, HSP 90, crystalline, GAPDH, ferritin H, ferritin L, cox 1, cox 2, and transferrin) produced, by for example, as alleles or strain differences, are disclosed.
• Table 4 e.g., cyclin Dl, cyclin B, cyclin Gl, weel, hTR2, CDC25b, GSK3 beta, protein kinase C alpha, C5, Cl inhibitor, IL-17r, IL-8, LIF, TNF-alpha, and IL-IOr, Alpha-1 antichymotry
• cyclin Dl such as cyclin Dl, cyclin B, cyclin Gl, weel, hTR2, CDC25b, GSK3 beta, protein kinase C alpha, C5, Cl inhibitor, IL-17r, IL-8, LIF, TNF-alpha, and IL-IOr, Alpha-1 antichymotrypsin, HSP 27, HSP 90, crystalline, GAPDH, ferritin H, ferritin L, cox 1, cox 2, and transferrin, and Table 5, such as HSP60, Dihydrolipoamide dehydrogenase, ER-60 protease, Glucose-6- phosphate dehydrogenase, ATP-synthase beta chain, Annexin 1, 14-3-3 protein epsilon,
• Prohibitin Phospoglycerate mutase 1, Apoliporotein AI, Superoxide dismutase, RNA-binding protein regulatory subunit, Chain A thioredoxin peroxidase B, RAS-related protein RAPlB, Tumor rejection antigen, Haptoglobin, Fibrin beta, actin-interacting protein 1 (AIPl), mitogen activated protein kinase I (MAPKI), actin or a fragment thereof, glutaraldehyde-3-phosphate dehydrogenase (GAPDH), transforming protein RhoA, acidic leucine-rich nuclear phosphoprotein 32 family member B (ANP32B or APRIL), peroxiredoxin ⁇ , an amyloid precursor protein (APP), an ⁇ -secretase, a ⁇ -secretase, a ⁇ -secretase, an A/3 peptide, Fe65, Tip ⁇ O, SERCA, PS1/2, nectin-la, or non-amyloid
• the expression of a biomarker can be assessed in one or more subjects diagnosed with a neurodegenerative and in one or more subjects who do not have the neurodegenerative disease.
• a biomarker whose expression varies between the two groups can be a validated biomarker. The larger the two groups of subjects are, the more reliable the validation.
• the expression level of a biomarker can also be assessed in a model system for neurodegenerative disease. For example, the level of expression can be tested in leukocyte-containing samples of an animal model for a neurodegenerative disease.
• Expression of a biomarker (or its homolog) can be assessed in an animal model of a neurodegenerative disease and in a control group.
• a biomarker, or homolog thereof, whose expression varies between the model animals and the control animals can be a validated biomarker.
• solid supports including, stable and mobile forms
• at least one address is a biomarker or ligand as disclosed herein.
• at least one address is the sequences, portion of the sequences, or variant of the sequences set forth in any of the nucleic acid sequences or peptide sequences disclosed herein or a ligand for said sequences.
• chips where at least one address is the sequences or part of the sequences set forth in any of the nucleic acid sequences disclosed herein or a nucleic acid that hybridizes thereto.
• chips where at least one address is the sequences of the peptide sequences disclosed herein or a ligand for said sequence.
• chips where at least one address is a variant of the sequences or part of the sequences set forth in any of the nucleic acid sequences disclosed herein or a nucleic acid that hybridizes to said nucleic acid variant. Also disclosed are chips where at least one address is a variant of the sequences or portion of sequences set forth in any of the peptide sequences disclosed herein or a ligand that binds to said variant peptide.
• Solid supports include stable supports like slides, chips, microarrays, and nanoarrays comprising any of the biomarkers or antibodies or non-antibody ligands for the biomarkers disclosed herein.
• Solid supports also include mobile supports like beads comprising any of the biomarkers or antibodies or non-antibody ligands for the biomarkers disclosed herein.
• nucleic acids and proteins can be represented as a sequence consisting of the nucleotides or amino acids.
• nucleotide guanosine can be represented by G or g.
• amino acid valine can be represented by VaI or V.
• Those of skill in the art understand how to display and express any nucleic acid or protein sequence in any of the variety of ways that exist, each of which is considered herein disclosed. Specifically contemplated herein is the display of these sequences on computer readable mediums, such as, commercially available floppy disks, tapes, chips, hard drives, compact disks, and video disks, or other computer ' readable mediums.
• kits that are drawn to reagents that can be used in practicing the methods disclosed herein.
• the kits can include any reagent or combination of reagent discussed herein or that would be understood to be required or beneficial in the practice of the disclosed methods.
• the kits could include primers to perform the amplification reactions discussed in certain embodiments of the methods, as well as the buffers and enzymes required to use the primers as intended.
• the kits could include one or more of i ⁇ iibioyiiklllirliiai IPdflcfcsed herein, as well as the buffers, labels, enzyme ⁇ secondary or tertiary antibodies, etc.
• diagnostic assays for neurodegenerative diseases comprise contacting a sample comprising a leukocyte or a lysate thereof with one or more antibodies or fragments thereof for a biomarker for a neurodegenerative disease.
• Antibodies for the disclosed biomarkers can be made my methods known in the art and as disclosed herein.
• compositions disclosed herein and the compositions necessary to perform the disclosed methods can be made using any method known to those of skill in the art for that particular reagent or compound unless otherwise specifically noted. 1. Nucleic acid synthesis
• One method of producing the disclosed proteins is to link two or tnore peptides or polypeptides together by protein chemistry techniques.
• peptides or polypeptides can be chemically synthesized using currently available laboratory equipment using either Fmoc or Boc (tert butyloxycarbonoyl) chemistry (Applied Biosystems, Inc., Foster City, CA).
• Fmoc or Boc (tert butyloxycarbonoyl) chemistry Applied Biosystems, Inc., Foster City, CA.
• a peptide or polypeptide corresponding to the disclosed proteins for example, can be synthesized by standard chemical reactions.
• a peptide or polypeptide can be synthesized and not cleaved from its synthesis resin whereas the other fragment of a peptide or protein can be synthesized and subsequently cleaved from the resin, thereby exposing a terminal group which is functionally blocked on the other fragment.
• peptide condensation reactions these two fragments can be co valently joined via a peptide bond at their carboxyl and amino termini, respectively, to form an antibody, or fragment thereof.
• the peptide or polypeptide is independently synthesized in vivo as described herein.
• advances in recombinant glycoprotein production methods which allow more cost effective production of human glycoproteins by colonies of transgenic rabbits (www.bioprotein.com) or by yeast strains carrying human N-glycosylation system enzymes (Hamilton, et al., Science, 2003;301:1244-6; Gerngross, Nature Biotechnology, 2004;22:1409) can be used.
• the first step is the chemoselective reaction of an unprotected synthetic peptide thioester with another unprotected peptide segment containing an amino-terminal Cys residue to give a thioester-linked intermediate as the initial covalent product. Without a change in the reaction conditions, this intermediate undergoes spontaneous, rapid intramolecular reaction to form a native peptide bond at the ligation site (Baggiolini, et al., FEBS Lett. 1992;307:97-101; Clark-Lewis, et al., J. Biol.
• DNA encoding the disclosed monoclonal antibodies can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies).
• Libraries of antibodies or active antibody fragments can also be generated and screened using phage display techniques, e.g., as described in U.S. Patents Nos. 5,804,440 and 6,096,441, which are incorporated by reference herein at least for their teachings of antibody preparation.
• the fragments can also include insertions, deletions, substitutions, or other selected modifications of particular regions or >ieidi-rl;i!dtiil; "
• modifications can provide for some additional property, such as to remove/add amino acids capable of disulfide bonding, to increase its bio-longevity, to alter its secretory characteristics, etc.
• the antibody or antibody fragment must possess a bioactive property, such as specific binding to its cognate antigen.
• Functional or active regions of the antibody or antibody fragment may be identified by mutagenesis of a specific region of the protein, followed by expression and testing of the expressed polypeptide. Such methods are readily apparent to a skilled practitioner in the art and can include site-specific mutagenesis of the nucleic acid encoding the antibody or antibody fragment. (Zoller, Curr. Opin. Biotechnol., 1992;3:348-354, which is incorporated by reference herein at least for its teachings of antibody preparation).
• human antibodies can be prepared using any technique. Examples of techniques for human monoclonal antibody production include those described by Cole, et al. (Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77, 1985) and by Boerner, et al. (J. Immunol., 1991;147(1):86 95), which are incorporated by reference herein at least for their teachings of antibody preparation. Human antibodies (and fragments thereof) can also be produced using phage display libraries (Hoogenboom, et al., J. MoI. Biol., 1991;227:381; Marks, et al., J. MoI. Biol.
• humanized antibodies can be generated according to the methods of Winter and co- workers (Jones, et al., Nature, 1986;321:522-5, Riechmann, et al., Nature, 1988;332:323-7, Verhoeyen et al., Science 1988;239: 1534-6), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Methods that can be used to produce humanized antibodies are also described in U.S. Patent Nos.
• compositions As well as making the intermediates leading to the compositions.
• methods that can be used for making these compositions, such as synthetic chemical methods and standard molecular biology methods. It is understood that the methods of making these and the other disclosed compositions are specifically disclosed.
• nucleic acid molecules produced by the process comprising linking in an operative way a nucleic acid molecule comprising a sequence that hybridizes under stringent hybridization conditions to a sequence set forth in Table 4 and a sequence controlling the expression of the nucleic acid.
• nucleic acid molecules produced by the process comprising linking in an operative way a nucleic acid molecule comprising a sequence encoding a protein such as HSP60, Dihydrolipoamide dehydrogenase, ER-60 protease, Glucose-6-phosphate dehydrogenase, ATP-synthase beta chain, Annexin 1, 14-3-3 epsilon, Prohibitin, Phospoglycerate mutase 1, Apoliporotein AI, Superoxide dismutase, RNA-binding protein regulatory subunit, Chain A thioredoxin peroxidase B, RAS-related protein RAPlB, Tumor rejection antigen, Haptoglobin, Fibrin beta, actin-interacting protein 1 (AIPl), mitogen activated protein kinase I (MAPKI), actin or a fragment thereof, glutaraldehyde-3 -phosphate dehydrogenase (GAPD
• l4f5 OKsciiiii lililiiifeleic acid molecules produced by the process comprising linking in an operative way a nucleic acid molecule comprising a sequence encoding a protein having 80% identity to a protein such as HSP60, Dihydrolipoamide dehydrogenase, ER-60 protease, Glucose-6-phosphate dehydrogenase, ATP-synthase beta chain, Annexin 1, 14-3-3 epsilon, Prohibitin, Phospoglycerate mutase 1, Apoliporotein AI, Superoxide dismutase, RNA-binding protein regulatory subunit, Chain A thioredoxin peroxidase B, RAS-related protein RAPlB, Tumor rejection antigen, Haptoglobin, Fibrin beta, actin-interacting protein 1 (ADP 1), mitogen activated protein kinase I (MAPKI), actin or
• ADP 1
• compositions as research tools 253.
• the disclosed compositions can be used in a variety of ways as research tools.
• compositions such as SEQ ID NOs: 1-257 can be used to study the effects of various therapies on a neurodegenerative disease.
• compositions can be used for example as targets in combinatorial chemistry protocols or other screening protocols to isolate molecules that possess desired functional properties related to a neurodegenerative disease (e.g., Alzheimer's and Parkinson's disease).
• a neurodegenerative disease e.g., Alzheimer's and Parkinson's disease.
• compositions can also be used diagnostic tools related to neurodegenerative diseases such as Alzheimer's and Parkinson's disease.
• RNA from each of these samples was extracted, hybridized and analyzed at different times.
• Sample 1 consisted of 8 AD and 7 control cases.
• Sample 2 consisted of 8 AD and 8 control cases.
• Sample 3 consisted of 5 AD, 4 control and 2 PD cases. Sample characteristics are summarized in Tables 1-3.
• AD subjects included in the study were diagnosed with probable or possible AD on the basis of NINCDS (McKhann G, et al., Neurology, 1984;34(7):939-944) and DSM IV criteria for AD. Examination by a neurologist was performed to confirm diagnosis and to measure disease severity. Disease severity was assessed using the Mini-Mental Status Examination (MMSE) (Folstein MF, et al., J. Psychiatric Res., 1975;12(3):189-198), the Clinical Dementia Rating scale (CDR) (Hughes CP, et al., British J. Psychiatry, 1982; 140:566-572), and the captivating Dementia Rating Scale (BDRS) (Blessed G, et al., British J. Psychiatry,
• RNA samples were collected and stored at minus 80°C until later use. The concentration and purity of samples were checked by OD 26 o /280 . It is understood that any RNA isolation procedure could be used. 4. Construction and hybridization of cDNA arrays
• the cDNA clones used are listed in Table 4.
• the dbEST database of the National Center for Biotechnology Information was searched for relevant 3'-cDNA clones and the clones were either purchased from distributors or gifts from various laboratories.
• the membranes were prehybridized at 42 0 C in hybridization solution (50% formamide/5X SSPE/5X Denhardt's solution/0. 1% SDS/ 10% dextran sulfate/50, ⁇ g/ml denatured salmon sperm DNA/100 ⁇ g/ml tRNA) for 3 hours before adding the RNA probes. After overnight incubation at 42°C, blots were washed in 2X SSC/0.1% SDS at 55°C for 1 hour, 2X SSC/0.1% SDS/10 ⁇ g/ml RNAse A at 37°C for 1 hour, and 2X SSC/0.1% SDS at 37°C for 1 hour. Membranes were then exposed to a storage phosphor screen. 5. Data acquisition and analysis 264. Hybridization intensity of each dot was detected by laser densitometric scanning
• AD Alzheimer's disease .
• tau phosphorylation by kinases also related to the cell cycle (Busciglio J, et al., Neuron, 1995;14(4):879-888; Ferreira A, et al., Molecular & Cellular Greenberg SM, et al., Proc. Nat. Acad. Sci.
• RNA profiling of the expression of multiple genes by peripheral leukocytes followed by canonical discriminant analysis can be used both as a biological tool for the analysis of molecular alterations in disease, as well as a tool for differentiation between Alzheimer's and control patients. These methods also suggest a potential to differentiate numerous other diseases. It is not the significant difference between individual genes (although a few genes have significant correlations) that provides a clear discrimination between patients with a specific disease and others, but rather an analysis based on weighted sums of many genes.
• Example 2 Inflammatory, cell cycle, and stress transcripts and molecular distinction of Alzheimer's disease from peripheral blood leukocytes
• AD subjects included in the study were diagnosed with probable or possible AD on the basis of NINCDS (McKhann G, et al., Neurology, 1984;34(7):939-944) and DSM IV criteria for AD. Examination by a neurologist was performed to confirm diagnosis and to severity was assessed using the Mini-Mental Status Examination (MMSE; Folstein et al., J. Psychiatric Res., 1975;12(3):189-198), the Clinical Dementia Rating scale (CDR; Hughes et al., British J. Psychiatry, 1982;140:566-572), and the captivating Dementia Rating Scale (BDRS; Surprise et al., British J.
• MMSE Mini-Mental Status Examination
• CDR Hughes et al., British J. Psychiatry, 1982;140:566-572
• BDRS Blessed Dementia Rating Scale
• AD cases Control subjects included in the study scored above 27 on the MMSE, while AD cases scored below 22.
• the mean CDR of AD cases in each of the three samples ranged from 1.2 to 1.5. Since these were not autopsy confirmed cases, the assignment of each case to a specified disease category relies on the accuracy of the clinical diagnosis. Any subject with a history of bleeding diathesis or coagulopathy was excluded. Blood samples were drawn by a phlebotomist and stored at 4°C until processed for RNA isolation (less than 8 hours).
• the cDNA clones represented in the arrays were selected based on previous microarray studies (e.g., Chow, et al., Proc. Natl. Acad. Sci. USA. 1998;95:9620-9625) and a subset of those of interest in the field of AD research.
• the dbEST database of the National Center for Biotechnology Information was searched for relevant 3' cDNA clones.
• the cDNA clones used in this study were gifts from many investigators or were from distributors of I.M.A.G.E. Consortium cDNA clones. 172 transcripts were represented in the arrays.
• the membranes were prehybridized at 42 0 C in I ⁇ C ' l ⁇ y ⁇ illll ⁇ o ⁇ it ⁇ in ⁇ i ⁇ 'formamide/SX SSPE/5X Denhardt's solution/0. 1% SDS/ 10% dextran sulfate/50, ⁇ g/ml denatured salmon sperm DNA/100 ⁇ g/ml tRNA) for 3 hours before adding the RNA probes.
• Hybridization intensity of each dot was detected by laser densitometric scanning (Phosphoimager, Molecular Dynamics). Values (counts) for each spot obtained by
• the multivariant analysis was performed on SAS/STATTM software from SAS Institute, Inc. (Gary, NC). This analysis determines the variables (messages) that best distinguish groups and assigns weights to each variable. The first canonical variable provides the best distinction between groups. The second canonical variable operates on the residual variance that remains unaccounted for by canonical variable 1.
• transcripts 30 into 5 subsets of 7 or 8 messages out of the total of 172 transcripts studied.
• Three of the subsets formed were based on hypotheses that specified systems known to be affected in AD brain would also be affected in AD leukocytes.
• These three sets of transcripts were those related to either cell stress (especially oxidative stress), inflammatory system, or cell cycle/apoptosis.
• Two ! i"OtI ' ef ' M>sy3IPbfef «liieif'inl composed of transcripts that approached significance in the t-test and one composed of transcripts chosen at random as a control for spurious results from the analytical methods used.
• These transcript sets were then utilized to analyze the data from three independent samples of early AD and control subjects. The statistical significance of the separation between AD and control cases resulting from canonical analysis was assessed by the WaId- Wolfowitz runs test (Siegel S, Nonparametric Statistics, McGraw-Hill, New York, N.Y. 1956:1-312).
• Multivariate canonical discriminant analysis was, however, able to deliver excellent distinction between peripheral blood leukocytes of early Alzheimer's disease and control subjects.
• the first study established that canonical discriminant analysis of the sets of transcripts related to cell stress, inflammatory system and cell cycle/apoptosis was able to distinguish AD from control samples with minimal overlap. Each point in each plot represents a composite "score" [canonical variable 1] for one individual.
• This score was determined by multivariate canonical discriminant analysis of the 8-10 transcripts selected to represent cell stress (e.g., Al ⁇ ha-1 antichymotrypsin, HSP 27, HSP 90, crystalline, GAPDH, ferritin H, ferritin L, cox 1, cox 2, and transferrin) (see Fig. 3A), inflammation (e.g., C5, Cl inhibitor, IL-17r, IL-8, LIF, TNF-alpha, and IL-IOr) (see Fig. 3B), or cell cycle (e.g., cyclin Dl, cyclin B, cyclin Gl, weel, hTR2, CDC25b, GSK3 beta, and protein kinase C alpha) (see Fig. 3C).
• cell stress e.g., Al ⁇ ha-1 antichymotrypsin, HSP 27, HSP 90, crystalline, GAPDH, ferritin H, ferritin L, cox 1, cox 2, and transferrin
• inflammation
• the classes of gene products shown here to distinguish AD from control peripheral blood leukocytes are also among those classes of gene products that are known to have altered expression in AD brain.
• the three classes of transcripts investigated do not appear to have performed equally well. Although transcripts related to cell stress and inflammatory system were quite consistent in their distinction of disease state, cell cycle transcripts were less consistent. Nevertheless, the data suggest that multivariate analysis of expression profiles of peripheral cells can be used in the study of molecular phenomena of Alzheimer's disease.
• Selected neuropathological/neurobiological aspects of AD can be consequences of altered expression of cell cycle, cell stress, and inflammation events, all of which are pivotal in the life of a cell.
• activation of cell cycle kinases by A beta leads to tau phosphorylation (Busciglio et al., Neuron. 1995;14(4):879-888; Greenberg et al., Proc. Nat. Acad. Sci. U.S.A., 1994;91(15):7104-7108), which produces the cytoskeletal disassembly required by cell division. Cytoskeleton disassembly then would have consequences for maintenance of neuronal processes, transport and the support of synapses.
• the meanings that may be extracted from array data are dependent on the array specifics and the analysis methods used.
• the combination of targeted arrays and analytical methods used was designed to test the hypothesis that selected molecular systems related to fundamental cell biology known to be affected in AD brain would also be found to be affected in peripheral blood leukocytes. Focused was specifically on transcripts related to inflammatory systems, cellular stress, and cell cycle/apoptosis.
• the targeted arrays used herein were, therefore, designed to include multiple probes related to each of these three systems. Rather than emphasize analytical methods designed to test AD/control differences of individual transcripts, a method of analysis that was able to test differences between AD and control profiles of gene expression by making simultaneous use of multiple transcripts was used. The classical method of canonical discriminant analysis was selected.
• This method makes use of knowledge of the existence of two (or more) groups to find the set of variables (transcripts) that best differentiates the groups.
• the analysis assigns a weight to each transcript, and these weights are used to calculate a "score" (e.g.,. canonical variable) for each person.
• the analysis is as described hereinbefore and was performed with the SAS/STATTM software. It is this score that is presented in Figures 3-5.
• Alzheimer's disease in ways that are suggestive of events in brain can be explained by communication between peripheral blood elements and the brain (e.g. Hickey WF, et al., 1991; see Hickey, 1999 for review). Furthermore, the permeability of the blood-brain barrier to such lF ixcEaii
• a beta peptides e.g. Farkas IG, et al., 2003
• selected A beta peptides have been shown to be increased in the peripheral circulation in AD (see Mzarry MC, 2004, for review).
• Parkinson's disease protein analysis identified a patient population which included 13 Parkinson's disease (PD) patients and 9 age-matched control patients. Fresh whole blood was drawn, red blood cells lysed and leukocytes harvested. Leukocyte protein concentrations were determined and protein integrity determined by SDS-PAGE electrophoresis followed by Coomassie blue staining. Equal amounts of leukocyte protein lysates were subjected to 2D-gel electrophoresis. Gels were silver stained, dried and scanned with a laser densitometer followed by limited computerized comparisons ( Figure 6). Protein spots that differ in intensity between PD and control patients were identified using Progenesis Discovery software (Nonlinear US A, Inc.; Durham, NC). Difference measurements subjected to statistical testing.
• Table 6 Provisionally identified proteins that differ between Parkinson's disease patients and control subjects.
• Protein concentration was determined and protein integrity assayed by SDS-PAGE electrophoresis followed by Coomassie-blue staining. Equal amounts of leukocyte protein lysates were subjected to 2D gel electrophoresis and gels were silver-stained, dried, and scanned with a laser densitometer followed by limited computerized comparisons. See Figure 10. Differentially expressed protein spots were identified using the Progenesis Discovery software and statistical testing (from Nonlinear Dynamics, Durham, NC). Nine spots were identified as either increasing or decreasing in patients on valproate therapy.
• biomarkers include actin-interacting protein 1 (AIPl), mitogen activated protein kinase I (MAPKI), actin or a fragment thereof, annexin Al, 14-3-3 protein epsilon, glutaraldehyde-3-phosphate dehydrogenase (GAPDH), transforming protein RhoA, acidic leucine-rich nuclear phosphoprotein 32 family member B (ANP32B or APRIL), or peroxiredoxin II.
• AIPl actin-interacting protein 1
• MAPKI mitogen activated protein kinase I
• actin or a fragment thereof annexin Al
• 14-3-3 protein epsilon 14-3-3 protein epsilon
• GPDH glutaraldehyde-3-phosphate dehydrogenase
• RhoA transforming protein RhoA
• APRIL acidic leucine-rich nuclear phosphoprotein 32 family member B
• peroxiredoxin II peroxiredoxin II.
• Arendt T Alzheimer's disease as a loss of differentiation control in a subset of neurons that retain immature features in the adult brain. Neurobiology of Aging. 2000;21(6):783-796.
• Braak H Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiology of Aging. 1997;18(4):351-357.
• Folstein MF Folstein SE and McHugh P. Mini-Mental state - practical method for grading cognitive state of patients for clinician. Journal of Psychiatric Research. 1975;12(3):189- 198.
• Gao Y. Pimplikar SW The gamma -secretase-cleaved C-terminal fragment of amyloid precursor protein mediates signaling to the nucleus. Proceedings of the National Academy of Sciences of the United States of America. 2001 ;98(26): 14979-14984.
• Beta-amyloid precursor protein is detectable on monocytes and is increased in Alzheimer's disease. Neurobiology of Aging. 1999;20(3):249- 257.
• PD Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease. Neurobiology of Disease, 12, 97-109, 2003.Yao P, and PD Coleman. Reduction of O-linked N-acetylglucosamine-modified assembly protein-3 in Alzheimer's disease. Journal of Neuroscience. 1998;18(7):2399-2411.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Cell Biology (AREA)
• Public Health (AREA)
• Organic Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• General Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Hematology (AREA)
• Veterinary Medicine (AREA)
• Biomedical Technology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Immunology (AREA)
• Molecular Biology (AREA)
• Urology & Nephrology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Neurology (AREA)
• Analytical Chemistry (AREA)
• Tropical Medicine & Parasitology (AREA)
• Virology (AREA)
• Rheumatology (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• Pain & Pain Management (AREA)
• Neurosurgery (AREA)
• Food Science & Technology (AREA)
• Physics & Mathematics (AREA)
• Zoology (AREA)
• Biochemistry (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=35907991

Family Applications (1)

Country Status (6)

Families Citing this family (47)

• 2005
  • 2005-07-19 AU AU2005274788A patent/AU2005274788A1/en not_active Abandoned
  • 2005-07-19 CA CA002574727A patent/CA2574727A1/en not_active Abandoned
  • 2005-07-19 JP JP2007522634A patent/JP2008506415A/ja not_active Withdrawn
  • 2005-07-19 EP EP05795150A patent/EP1797425A2/de not_active Withdrawn
  • 2005-07-19 WO PCT/US2005/025491 patent/WO2006020269A2/en active Application Filing
  • 2005-07-19 CN CNA2005800314065A patent/CN101137903A/zh active Pending

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events